

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2017**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED/ACCEPTED (2017)			
S0033	Correlation of long-term results of imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) with next generation sequencing results: Analysis of SWOG phase III intergroup trial S0033. MC Heinrich, C Rankin, CD Blanke, GD Demetri, EC Borden, CW Ryan, M von Mehren, ME Blackstein, DA Priebe, WD Tap, RG Maki, CL Corless, JA Fletcher, K Owzar, JJ Crowley, RS Benjamin, LH Baker. <i>JAMA Oncology</i> , Jul 1;3(7):944-952, 2017. 2017 Feb 9 [Epub ahead of print]. PMID28196207 https://www.ncbi.nlm.nih.gov/pubmed/28196207	12/15/00	9/1/01
S0518	Phase III prospective randomized comparison trial of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in advanced, poor prognosis carcinoid patients: SWOG S0518. JC Yao, KA Guthrie, C Moran, JR Strosberg, MH Kulke, J Ang Chan, N Loconte, RR McWilliams, EM Wolin, B Mattar, S McDonough, H Chen, CD Blanke, HS Hochster. <i>Journal of Clinical Oncology</i> May 20;35(15):1695-1703, 2017. Apr 6 [Epub ahead of print]. PMID28384065; PMC5455764 https://www.ncbi.nlm.nih.gov/pubmed/28384065	12/1/07	9/1/12
S1115	Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. V Chung, S McDonough, PA Philip, D Cardin, A Wang-Gillam, L Hui, MA Tejani, TE Seery, IA Dy, T Al Baghdadi, AE Hendifar, LA Doyle, AM Lowy, KA Guthrie, CD Blanke, HS Hochster. <i>JAMA Oncology</i> Apr 1;3(4):516-522, 2017; 2016 Dec 15 [Epub ahead of print]. PMID27978579 https://www.ncbi.nlm.nih.gov/pubmed/27978579	8/15/12	5/15/14
CALGB/ SWOG 80405	Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: A randomized trial. AP Venook, D Niedzwiecki, H-J Lenz, F Innocenti, B Fruth, JA Meyerhardt, D Schrag, C Greene, BH O'Neil, JE Shaw, JN Atkins, A El-Khoueiry, S Berry, BN Polite, EM O'Reilly, RM Goldberg, HS Hochster, RL Schilsky, MM Bertagnolli, RJ Mayer, CD Blanke. <i>JAMA</i> Jun 20; 317(23):2392-2401, 2017. PMID28632865; PMC5545896 https://www.ncbi.nlm.nih.gov/pubmed/28632865	10/1/05	3/1/12

C89803 Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). MA Fuchs, C Yuan, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, F Innocenti, RS Warren, MM Bertagnolli, S Ogino, EL Giovannucci, E Horvath, JA Meyerhardt, K Ng. Annals of Oncology Jun 1;28(6): 1359-1367, 2017. PMID: 28327908 [see also Ca Surv Cmte] <https://www.ncbi.nlm.nih.gov/pubmed/?term=hantel+a+vitamin+d>

GI MANUSCRIPTS SUBMITTED (2017)

S0713	SWOG S0713: A phase II study of cetuximab added to induction chemotherapy of oxaliplatin and capecitabine , followed by neoadjuvant chemoradiation for locally advanced rectal cancer. CG Leichman, SL McDonough, SR Smalley, KG Billingsley, H-J Lenz, MA Beldner, AF Hezel, MR Velasco, KA Guthrie, CD Blanke, HS Hochster. <u>Clinical Colorectal Cancer</u> , under review.	2/1/09	4/15/13
-------	---	--------	---------

C89803 Artificially Sweetened Beverage Intake and Outcome in Stage III Colon Cancer: Results from CALGB 89803 (Alliance). C Fuchs, B Guercio, S Zhang, D Niedzwiecki, Z Yee, Y Li, A Babic, V Morales-Oyarvide, L Saltz , RJ Mayer, R Mowat, R Whittom, A Hantel, A Benson, DM Atienza, M Messino, H Kindler, A Venook, S Ogino, E Zoltick, M Stempfer, K Ng, K Wu, W Willett, E Giovannucci, J Meyerhardt . Journal of Clinical Oncology, submitted. [see also Ca Surv Cmte]

C89803 Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis in relation to cancer recurrence and survival. E Van Blarigan, C Fuchs, D Niedzwiecki, X Ye, S Zhang, M Song, L Saltz, R Mayer, R Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, E Giovannucci, J Meyerhardt. Cancer Epidemiology, Biomarkers & Prevention, submitted.

N0147	Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). MR Mahoney, JA Sloan, JM Hubbard, AD Tan, H Liu, RM Goldberg, SG Nair, AF Shields, S Gill, B Jahagirdar, AB Benson, DJ Sargent, SR Alberts. <u>Journal of Patient Reported Outcomes</u> , submitted.	8/1/04	11/25/09
-------	--	--------	----------

GI ABSTRACTS ACCEPTED/PRESENTED/PUBLISHED (2017)

S1201	A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 (Excision Repair Cross-Complementing 1) for advanced/ metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer: SWOG S1201. S Iqbal, S McDonough, H-J Lenz, D Ilson, B Burtness, CS Nangia, A Barzi, CJ Schneider, J Liu, E Dotan, KA Guthrie, HS Hochster. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion; J Clin Oncol 35, 2017 (suppl; abstr 4009). http://abstracts.asco.org/199/AbstView_199_186970.html	2/8/12	4/1/15
-------	--	--------	--------

S1310	SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer. R Kim, S McDonough, A El-Khoueiry, T Bekaii-Saab, S Stein, V Sahai, GP Keogh, EJ Kim, AD Baron, AB Siegel, A Barzi, K Guthrie, M Javle, Howard Hochster. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion. J Clin Oncol 35, 2017 (suppl; abstr 4016). http://abstracts.asco.org/199/AbstView_199_187183.html	2/15/14	5/15/15
S1406	Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). S Kopetz, S McDonough, H Lenz, A Magliocco, C Atreya, L Diaz, C Allegra, K Raghav, V Morris, SE Wang, C Lieu, K Guthrie, H Hochster. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral presentation; J Clin Oncol 35, 2017 (suppl; abstr 3505). http://abstracts.asco.org/199/AbstView_199_194502.html	11/13/14	4/1/16
S1406	Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). S Kopetz, S McDonough, VK Morris, H-J Lenz, AM Magliocco, CE Atreya, LA Diaz, CJ Allegra, CH Lieu, SE Wang, SG Eckhardt, TJ Semrad, K Kaberle, K Guthrie, HS Hochster. ASCO GI Cancers Symposium (Jan 19-21, 2017, San Francisco, CA), poster; <u>Journal of Clinical Oncology</u> 35, 2017 (suppl 4S; abstract 520). http://meetinglibrary.asco.org/content/176737-195	11/13/14	4/1/16
S1505	SWOG S1505: a randomized phase II study of peri-operative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. D Sohal, S McDonough, S Ahmad, N Gandhi, M Shaalan Beg, A Wang-Gillam, K Guthrie, A Lowy, P Philip, H Hochster. ASCO GI Cancers Symposium (January 19-21, 2017, San Francisco, CA), TIPS, poster; <u>J Clin Oncol</u> 35, 2017 (suppl 4S; abstract TPS508). http://meetinglibrary.asco.org/content/176671-195	10/12/15	n/a
S1505	SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. SA Ahmad, S McDonough, DPS Sohal, N Gandhi, MS Beg, A Wang-Gillam, K Guthrie, AM Lowy, PA Philip, HS Hochster. American Hepato-Pancreato-Biliary Association Annual Meeting (March 29-April 2, 2017, Miami Beach, Florida), oral.	10/12/15	n/a
S1513	Randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. EG Chiorean, S McDonough, PA Philip, E Swisher, M Pishvaian, K Guthrie, A Lowy, H Hochster. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session. J Clin Oncol 35, 2017 (suppl; abstr TPS4147). http://abstracts.asco.org/199/AbstView_199_186366.html	9/1/216	

C80405	Associations of physical activity with survival and progression in metastatic colorectal cancer: results from CALGB 80405 (Alliance). B Guercio, A Venook, D Niedzwiecki, S Zhang, K Sato, C Fuchs, H-J Lenz, F Innocenti, B Fruth, E Van Blarigan, B O'Neil, J Edward Shaw, B Polite, H Hochster, J Atkins, R Goldberg, R Mayer, M Bertagnolli, C Blanke, J Meyerhardt. ASCO GI Cancers Symposium (Jan 19-21, 2017, San Francisco, CA), poster. J Clin Oncol 35, 2017 (suppl 4S; abstract 659). http://meetinglibrary.asco.org/content/175855-195	10/1/05	3/1/12
C80405	Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). H-J Lenz, F-S Ou, AP Venook, HS Hochster, D Niedzwiecki, R Goldberg, R Mayer, M Bertagnolli, CD Blanke, T Zemla, X Qu, O Kabbarah, F Innocenti. American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), oral; J Clin Oncol 35, 2017 (suppl; abstr 3511). http://abstracts.asco.org/199/AbstView_199_188347.html	10/1/05	3/1/12
C80405	Primary tumor location is an independent prognostic maker from CMS and MSI for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance). AP Venook, F-S Ou, F Innocenti, HS Hochster, D Niedzwiecki, R Goldberg, R Mayer, M Bertagnolli, CD Blanke, T Zemla, X Qu, O Kabbarah, H-J Lenz. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral; J Clin Oncol 35, 2017 (suppl; abstr 3503). http://abstracts.asco.org/199/AbstView_199_183226.html	10/1/05	3/1/12
C80405	Somatic DNA mutations, mutational load (ML), and MSI status: association with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 Alliance). F Innocenti, F-S Ou, T Zemla, D Niedzwiecki, X Qu, R Tam, S Mahajan, R Goldberg, R Mayer, M Bertagnolli, HS Hochster, C Blanke, A Venook, H Lenz, O Kabbarah. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral; J Clin Oncol 35, 2017 (suppl; abstr 3504). http://abstracts.asco.org/199/AbstView_199_192191.html	10/1/05	3/1/12
C80702/other	Prospective pooled analysis of six phase III trials investigating duration of adjuvant oxaliplatin-based therapy (3 versus 6 months) for patients with stage III colon cancer: The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. Q Shi, A Sobrero, A Shields, T Yoshino, J, J Taieb, I Souglakos, R Kerr, R Labianca, J Meyerhardt, F Bonnetain, T Watanabe, I Mpoukovinas, L Renfro, A Grothey, D Niedzwiecki, V Torri, T Andre, D Sargent, T Iveson. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral, plenary; J Clin Oncol 35, 2017 (suppl; abstr LBA1). http://abstracts.asco.org/199/AbstView_199_188616.html	8/15/10	11/20/15

C89803	American cancer society (ACS) nutrition and physical activity guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). EL Van Blarigan, CS Fuchs, D Niedzwiecki, X Ye, S Zhang, M Song, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, WC Willett, EL Giovannucci, JA Meyerhardt. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), oral; J Clin Oncol 35, 2017 (suppl; abstr 10006). http://abstracts.asco.org/199/AbstView_199_193741.html	7/15/00	5/15/01
C89803	Nut consumption and survival in stage III colon cancer patients: results from CALGB 89803 (Alliance). T Fadelu, D Niedzwiecki, S Zhang, X Ye, L Saltz, R Mayer, R Mowat, R Whittom, A Hantel, A Benson, Daniel Atienza, M Messino, H Kindler, A Venook, S Ogino, K Ng, EL Giovannucci, J Meyerhard, Y Bao, C Fuchs. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 3517). http://abstracts.asco.org/199/AbstView_199_189653.html	7/15/00	5/15/01
C89803	Long-chain omega-3 fatty acid and fish intake after colon cancer diagnosis and disease-free, recurrence-free, and overall survival in CALGB 89803 (Alliance). EL Van Blarigan, CS Fuchs, D Niedzwiecki, X Ye, S Zhang, M Song, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, WC Willett, EL Giovannucci, JA Meyerhardt. ASCO GI Cancers Symposium (Jan 19-21, 2017, San Francisco, CA), poster. J Clin Oncol 35, 2017 (suppl 4S; abstract 585). http://meetinglibrary.asco.org/content/176704-195	7/15/00	5/15/01
N0147	Genetic correlates of therapeutic toxicities of stage III colon cancer patients treated with adjuvant FOLFOX+/-cetuximab (NCCTG N0147, Alliance). PA Newcomb, W Sun, X Hua, B Banbury, A Phipps, JM Kocarnik, TA Harrison, Q Shi, F Sinicrope, S Thibodeau, E Chan, S Gill, RM Goldberg, M Kahlenberg, S Nair, A Shields, U Peters, SR Alberts, AT Chan. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session; J Clin Oncol 35, 2017 (suppl; abstr 3604). http://abstracts.asco.org/199/AbstView_199_193045.html	8/1/04	11/25/09
N0147	Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/-cetuximab chemotherapy: NCCTG N0147 (Alliance). FA. Sinicrope, Q Shi, TC Smyrk, RM Goldberg, E Heying, E Chan, S Gill, M Kahlenberg, S Nair, A Shields, DJ Sargent, MN Pollak, SR Alberts. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion; J Clin Oncol 35, 2017 (suppl; abstr 3516). http://abstracts.asco.org/199/AbstView_199_193534.html	8/1/04	11/25/09

N0147	Association of an immunoscore with survival of stage III colon cancer (CC) patients treated with adjuvant FOLFOX: NCCTG N0147 (Alliance). FA Sinicrope, Q Shi, F Hermitte, E Heying, E Chan, S Gill, RM Goldberg, MS Kahlenberg, S Nair, AF Shields, DJ Sargent, J Galon, S Alberts. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster; J Clin Oncol 35, 2017 (suppl; abstr 3579). http://abstracts.asco.org/199/AbstView_199_193534.html	8/1/04	11/25/09
N0147	Association of micropapillary architecture and high tumor budding with prognosis in patients with stage III colon cancer from a FOLFOX-based adjuvant chemotherapy Trial: NCCTG N0147 (Alliance). HE Lee, Q Shi, N Foster, DJ Sargent, E Chan, S Gill, M Kahlenberg, S Nair, AF Shields, RM Goldberg, SR Alberts, FA Sinicrope, TC Smyrk. USCAP 2017 Meeting (March 4-10, 2017, San Antonio, TX), poster. Mod Pathol 2017;30(S2):181A. https://www.nature.com/modpathol/journal/v30/n2s/pdf/modpathol2016249a.pdf	8/1/04	11/25/09
N0147	Pre-diagnostic physical activity and outcomes in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). A Phipps, Q Shi, E Chan, S Gill, RM Goldberg, S Hardikar, PJ Limburg, PA Newcomb, AF Shields, FA Sinicrope, TJ Zemla, DJ Sargent, SR Alberts. American Society of Preventive Oncology (March 11-14, 2017, Seattle, Washington), poster.	8/1/04	11/25/09
R9704	Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer. TS Hong, KA Winter, CS Fuchs, WF Regine, RA Abrams, H Safran, JP Hoffman, AB Benson, JS MacDonald, TC Kasunic, JF Strauss, T DiPetrillo, PJ Stella, Y Chen, RA Burger, CH Crane. ASCO GI Cancers Symposium (Jan 19-21, 2017, San Francisco, CA), poster; J Clin Oncol 35, 2017 (suppl 4S; abstract 369). http://meetinglibrary.asco.org/content/176683-195	5/1/99	7/6/02
Multiple*	Patterns of osteoporosis (OP) in survivors of colorectal cancer (CRC) enrolled on SWOG trials. A Barzi, D Hershman, C Till, H Lenz, J Unger. American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session. J Clin Oncol 35, 2017 (suppl; abstr 10056). http://abstracts.asco.org/199/AbstView_199_184332.html [S9304, S9415, and S9420]	n/a	n/a

GI ABSTRACTS SUBMITTED (2017)
(embargoed)

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2016**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED/ (2016)			
Multiple/S9415	Determinants of early mortality among 37,568 patients with colon cancer who participated in 25 clinical trials from the Adjuvant Colon Cancer Endpoints Database. WY Cheung, LA Renfro, D Kerr, A de Gramont, LB.Saltz, A Grothey, SR Alberts, T Andre, KA Guthrie, R Labianca, G Francini, J-F Seitz, C O'Callaghan, C Twelves, E Van Cutsem, DG Haller, G Yothers, DJ Sargent. <u>Journal of Clinical Oncology</u> , Apr 10;34(11):1182-1189, 2016. 2016 Feb 8 [Epub ahead of print]. PMID: 26858337; PMC4933130 http://www.ncbi.nlm.nih.gov/pubmed/26858337	n/a	n/a
Multiple/S9415	Validity of Adjuvant! Online in older patients with stage III colon cancer based on 2967 patients from the ACCENT database. D Papamichael, LA Renfro, C Matthaiou, G Yothers, L Saltz, K Guthrie, E Van Cutsem , HJ Schmoll, R Labianca , T André, M O'Connell, SR Alberts, DG Haller DG, P Kountourakis, D Sargent for Adjuvant Colon Cancer Endpoints (ACCENT) Group. <u>Journal of Geriatric Oncology</u> 2016 Jul 25. pii: S1879-4068 (16)30088-1. doi: 10.1016/j.jgo.2016.07.002. [Epub ahead of print] PMID27468630; PMC5159186 http://www.ncbi.nlm.nih.gov/pubmed/27468630	n/a	n/a
A021101	Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. MHG Katz, Q Shi, SA Ahmad, JM Herman, R de W Marsh, E Collisson, L Schwartz, W Frankel, R Martin, W Conway, M Truty, H Kindler, AM Lowy, T Bekaii-Saab, P Philip, M Talamonti, D Cardin, N LoConte, P Shen, JP Hoffman, AP Venook. <u>JAMA Surgery</u> Jun 8:e161137, 2016. PMID27275632 http://www.ncbi.nlm.nih.gov/pubmed/27275632		
N0147	Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). AM Lee, Q Shi Qian; SR Alberts, DJ Sargent, FA Sinicrope, JL Berenberg, A Grothey, B Polite, E Chan, S Gill, MS Kahlenberg, SG Nair, AF Shields, RM Goldberg, RB Diasio. <u>Pharmacogenetics and Genomics</u> , Mar;26(3): 133-137, 2016. PMID26658227; PMC4738010 http://www.ncbi.nlm.nih.gov/pubmed/26658227	8/1/04	11/25/09

N0147	Alcohol consumption and colon cancer prognosis among participants in North Central Cancer Treatment Group phase III trial N0147. A Phipps, Q Shi, PJ Limburg, GD Nelson, DJ Sargent, FA Sinicrope, E Chan, S Gill, RM Goldberg, M Kahlenberg, S Nair, AF Shields, PA Newcomb, SR Alberts, for the Alliance for Clinical Trials in Oncology. <u>International Journal of Cancer</u> , Sep 1;139(5):986-995, 2016; 2016 Apr 8 [Epub ahead of print]. PMID27060850; PMC4911257 http://www.ncbi.nlm.nih.gov/pubmed/27060850	8/1/04	11/25/09
N0147	Relationship between metformin use and recurrence and survival in patients with resected stage III colon cancer receiving adjuvant chemotherapy: results from North Central Cancer Treatment Group N0147 (Alliance). P Singh, Q Shi, N Foster, A Grothey, S Nair, E Chane, A Shields, R Goldberg, S Gill, M Kahlenberg, F Sinicrope, D Sargent, SR Alberts. <u>Oncologist</u> 2016 Dec;21(12): 1509-1521. Epub 2016 Nov 23. PMID27881709; PMC5153338. [also under Cancer Survivorship Committee] https://www.ncbi.nlm.nih.gov/pubmed/27881709	8/1/04	11/25/09

GI ABSTRACTS PUBLISHED/PRESENTED/PUBLISHED (2016)

S1505	SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as therapy for resectable pancreatic adenocarcinoma. DPS Sohal, KA Guthrie, SA Ahmad, NS Gandhi, MS Beg, A Wang-Gillam, S McDonough, AM Lowy, PA Philip, HS Hochster. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), Trials in Progress, TIPS ("Trials in Progress") poster session. <u>J Clin Oncol</u> 34, 2016 (suppl; abstr TPS4151). http://abstract.asco.org/176/AbstView_176_164440.html	10/12/15	n/a
C80405	Impact of primary (1 ^o) tumor location on overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405. A Venook, D Niedzwiecki, F Innocenti, B Fruth, C Greene, B O'Neil, J Shaw, B Polite, H Hochster, C Blanke, R Goldberg, R Schilsky, R Mayer, M Bertagnolli, H Lenz. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation. <u>J Clin Oncol</u> 34, 2016 (suppl; abstr 3504). http://abstract.asco.org/176/AbstView_176_161936.html	10/1/05	3/1/12
C80405	Blood-Based Biomarkers in Patients (pts) with Metastatic Colorectal Cancer (mCRC) Treated with FOLFOX or FOLFIRI + Bevacizumab (Bev), Cetuximab (Cetux), or Bev + Cetux: Results from CALGB 80405 (Alliance). AB Nixon, AB Sibley, AJ Hatch, Y Liu, C Jiang, F Mulkey, MD Starr, JC Brady, D Niedzwiecki, F Innocenti, AP Venook, H Hochster, H-J Lenz, BH O'Neil, K Owzar, HI Hurwitz. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. <u>J Clin Oncol</u> 34, 2016 (suppl; abstr 3597) http://abstract.asco.org/176/AbstView_176_169258.html	10/1/05	3/1/12

C80405	Variants associated with high grade bevacizumab-induced hypertension identified by exome sequencing: CALGB 80405 (Alliance). M Li, F Mulkey, C Jiang, B O'Neil, D Niedzwiecki, P Friedman, H Hochster, H-J Lenz, AP Venook, K Owzar, DL Kroetz. American Society for Clinical Pharmacology and Therapeutics (March 8-12, San Diego, CA), late breaking poster session. abst. #LB-041, p. 164. http://www.ascpt.org/Portals/8/docs/Meetings/2016%20Annual%20Meeting/Final%20Program.pdf	10/1/05	3/1/12
C80802	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)- CALGB 80802. GK Abou-Alfa, D Niedzwiecki, J Knox, A Kaubisch, A Siegel, B Tan, T Alcindor, T Bekaii Saab, M Bertagnolli, A Venook. ASCO GI Cancers Symposium (1/21/16 - 1/23/2016, San Francisco, CA); <i>J Clin Oncol</i> 34, (suppl 4S; abstr 192), 2016. http://meetinglibrary.asco.org/content/159480-173	6/1/11	5/21/15
C80802	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). G Abou-Alfa, D Niedzwiecki, J Knox, A Kaubisch, J Posey, B Tan, P Kavan, R Goel, P Lammers, T Bekaii-Saab, V Channing Tam, L Rajdev, R Kelley, A Siegel, J Balletti, J Harding, L Schwartz, R Goldberg, M Bertagnolli, A Venook. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 34, 2016 (suppl; abstr 4003). http://abstract.asco.org/176/AbstView_176_171166.html	6/1/11	5/21/15
E5204	Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (Bev) for patients (pts) with stage II or III rectal cancer receiving pre-operative chemoradiation: E5204 coordinated by the Eastern Cooperative Oncology Group. AB Benson III, NJ Meropol, P Catalano, F Zhao, E Sigurdson, A Bapsi Chakravarthy, SR Hamilton, PJ Flynn, K Kiel, C Gail Leichman, NJ Petrelli, FA Sinicrope, J Tepper, J Sloan, J Meyerhardt, L Wagner, P O'Dwyer. American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session. <i>J Clin Oncol</i> 34, 2016 (suppl; abstr 3616). http://abstract.asco.org/176/AbstView_176_168866.html	4/15/06	4/29/09

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2015**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED (2015)			
S0502	S0502: A SWOG phase III randomized study of imatinib, with or without bevacizumab, in patients with untreated metastatic or unresectable gastrointestinal stromal tumors. CD Blanke, CJ Rankin, CL Corless, J Eary, K Mulder, SH Okuno, S George, MC Heinrich. <u>The Oncologist</u> Dec;20(12):1353-1354, 2015. PMID26576593; PMC4679092 http://www.ncbi.nlm.nih.gov/pubmed/26576593	4/15/08	10/1/09
S0809	SWOG S0809: A phase II intergroup trial of adjuvant capecitabine/gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. E Ben-Josef, KA Guthrie, AB El-Khoueiry, CL Corless, MM Zalupski, AM Lowy, CR Thomas, Jr., SR Alberts, LA Dawson, KC Micetich, MB Thomas, AB Siegel, CD Blanke. <u>Journal of Clinical Oncology</u> Aug 20;33(24):2617-2622, 2015; 2015 May 11 [Epub ahead of print]. PMID25964250; PMC4534524 http://www.ncbi.nlm.nih.gov/pubmed/25964250	12/1/08	10/1/12
S1005	A phase II study of MK-2206, an allosteric inhibitor of AKT as second line therapy for advanced gastric and gastro-esophageal junction cancer, a SWOG cooperative group trial (S1005). RK Ramanathan, SL McDonough, H F Kennecke, S Iqbal, JC Baranda, TE Seery, HJ Lim, AF Hezel, GM Vaccaro, CD Blanke. <u>Cancer</u> Jul 1;121(13):2193-2197, 2015. PMID25827820; PMC4589423 http://www.ncbi.nlm.nih.gov/pubmed/25827820	1/1/11	5/1/13
S9304	Pharmacogenetic analysis of INT 0144 trial: association of polymorphisms with survival and toxicity in rectal cancer patients treated with 5-FU and radiation. P Bohanes, CJ Rankin, CD Blanke, T Winder, CM Ulrich, SR Smalley, K Danenberg, KW Makar, W Zhang, JK Benedetti, H-J Lenz. <u>Clinical Cancer Research</u> Apr 1;21(7):1583-1590, 2015. PMID25589620 PMC4566931 http://www.ncbi.nlm.nih.gov/pubmed/25589620	3/1/94	8/1/00
C89803	Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. K Ng, JA Meyerhardt, A Chan, K Sato, J Chan, D Niedzwiecki, L Saltz, R Mayer, A Benson, P Schaefer, R Whittom, A Hantel, R Goldberg, A Venook, S Ogino, E Giovannucci, C Fuchs. <u>Journal of the National Cancer Institute</u> , 107(1): dju345, 2015. PMID25432409; PMC4271076 http://www.ncbi.nlm.nih.gov/pubmed/25432409	7/15/00	5/15/01

C89803	Coffee intake, recurrence and mortality in stage III colon cancer: results from CALGB 89803 (Alliance). CS Fuchs, BJ Guercio, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom; A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, FB Hu, S Ogino, K Wu, WC Willett, E Giovannucci, JA Meyerhardt. <u>Journal of Clinical Oncology</u> , 2015 Nov 1;33(31):3598-3607, 2015; 2015 Aug 17 [Epub ahead of print]. PMID26282659; PMC4622099 http://www.ncbi.nlm.nih.gov/pubmed/26282659	7/15/00	5/15/01
NSABP R-04	Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. CJ Allegra, G Yothers, MJ O'Connell, RW Beart, TF Wozniak, HC Pitot, AF Shields, JC Landry, DP Ryan, A Arora, LS Evans, N Bahary, G Soori, JF Eakle, JM Robertson, DF Moore Jr, MR Mullane, BT Marchello, PJ Ward, S Sharif, MS Roh, N Wolmark. <u>Journal of the National Cancer Institute</u> 107(11): djv248, 2015. PMID26374429 http://www.ncbi.nlm.nih.gov/pubmed/26374429	4/15/06	8/16/10
Multiple/S9415*	Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population. LA Renfro, A Grothey, D Kerr, DG Haller, T André, E Van Cutsem, L Saltz, R Labianca, CL Loprinzi, SR Alberts, H Schmoll, C Twelves, G Yothers, DJ Sargent for the Adjuvant Colon Cancer Endpoints (ACCENT) Group. <u>Annals of Oncology</u> May;26(5):950-8, 2015; 2015 Feb 19 [Epub ahead of print]. PMID25697217; PMC4405281; *Multiple groups and studies including S9415; Collaborators: K Guthrie and CD Blanke. http://www.ncbi.nlm.nih.gov/pubmed/25697217	12/1/94	12/15/99

GI ABSTRACTS ACCEPTED/PRESENTED/PUBLISHED (2015)

S0518	SWOG S0518: phase III prospective randomized comparison of depot octreotide plus interferon alpha versus depot octreotide plus bevacizumab (NSC #704865) in advanced, poor prognosis carcinoid patients (NCT00569127). JC Yao, K Guthrie, C Moran, JR Strosberg, MH Kulke, J Ang Chan, N Loconte, RR McWilliams, EM Wolin, B Mattar, S McDonough, H Chen, CD Blanke, HS Hochster. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <u>J Clin Oncol</u> 33:5s, (suppl; abstr 4004), 2015. http://abstracts.asco.org/156/AbstView_156_146526.html	12/1/07	9/1/12
S0713	SWOG S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX), capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). CG Leichman, SL McDonough, SR Smalley, KG Billingsley, H-J Lenz, A Hezel, M Velasco, M Beldner, K Guthrie, C Blanke, HS Hochster. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster discussion. <u>J Clin Oncol</u> 33:5s (suppl; abstr 3516), 2015. http://abstracts.asco.org/156/AbstView_156_143177.html	2/1/09	4/15/13

S1115	SWOG S1115: randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in patients with metastatic pancreatic cancer after prior chemotherapy. V Chung, S McDonough, PA Philip, Dana Backlund Cardin, A Wang-Gillam, LHui, AM Lowy, KA Guthrie, CD Blanke, HS Hochster. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr 3516), 2015. http://meetinglibrary.asco.org/content/147234-156	8/15/12	5/15/14
S1310	SWOG S1310 Randomized phase II trial of single agent MEK inhibitor trametinib vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer. R Kim, S McDonough, A El-Khoueiry, T Bekaii-Saab, K Guthrie, H Hochster. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr TPS4142), 2015. http://abstracts.asco.org/156/AbstView_156_150637.html	2/15/14	n/a
S1406	S1406: Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). S Kopetz, S McDonough, V Morris, HJ Lenz, AM Magliocco, C Atreya, L Diaz, C Allegra, C Lieu, SG Eckhardt, T Semrad, K Kaberle, K Guthrie, H Hochster. ASCO Gastrointestinal Cancers Symposium (January 15-17, 2015, in San Francisco, CA), poster presentation. <i>Journal of Clinical Oncology</i> 33 (suppl 3; abstr TPS790), 2015. http://meetinglibrary.asco.org/content/140390-158	11/13/14	n/a
A021101	Intergroup pilot study of preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by capecitabine-based chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): initial results from Alliance Trial A021101. MHG Katz, Q Shi, S Ahmad, J Herman, R Marsh, E Collisson, L Schwartz, H Kindler, AM Lowy, AP Venook. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s (suppl; abstr 4008), 2015. http://abstracts.asco.org/156/AbstView_156_147695.html	5/15/13	n/a
C80405	Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: economic analysis of CALGB/SWOG 80405. D Schrag, A Dueck, M Naughton, D Niedzwiecki, C Earle, J Shaw, A Grothey, H Hochster, C Blanke, AP Venook. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s (suppl; abstr 6504), 2015. http://abstracts.asco.org/156/AbstView_156_152903.html	10/1/05	3/1/12
C/S80405	Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). K Ng, AP Venook, K Sato, BW Hollis, D Niedzwiecki, C Ye, I-W Chang, BH O'Neil, F Innocenti, H-J Lenz, CD Blanke, RJ Mayer, CS Fuchs, JA Meyerhardt. ASCO Gastrointestinal Cancers Symposium (January 15-17, 2015, in San Francisco, CA), poster presentation. <i>Journal of Clinical Oncology</i> 33 (suppl 3; abstr 507), 2015. http://meetinglibrary.asco.org/content/139861-158	10/1/05	3/1/12

C/S80405	Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance). K Ng, AP Venook, K Sato, BW Hollis, D Niedzwiecki, C Ye, I-W Chang, BH O'Neil, F Innocenti, H-J Lenz, CD Blanke, RJ Mayer, CS Fuchs, JA Meyerhardt. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s (suppl; abstr 3503), 2015. http://abstracts.asco.org/156/AbstView_156_149805.html	10/1/05	3/1/12
C/S80405	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405. V Heinemann, D Niedzwiecki, R Pearline, H-J Lenz, F Innocenti, HS Hochster, A Grothey, RM Goldberg, RJ Mayer, RL Schilsky, MM Bertagnolli, CD Blanke, AP Venook, S Stinzinger, BH O'Neil. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr 3585), 2015. http://abstracts.asco.org/156/AbstView_156_150067.html	10/1/05	3/1/12
C/S80405	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. F Innocenti, K Owzar, C Jiang, AB Sibley, D Niedzwiecki, MM Bertagnolli, PN Friedman, Y Furukawa, M Kubo, MJ Ratain, CD. Blanke, H-J Lenz, AP Venook, HL McLeod. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <i>J Clin Oncol</i> 33:5s (suppl; abstr 3599), 2015. http://abstracts.asco.org/156/AbstView_156_151613.html	10/1/05	3/1/12
C/S80405	A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405. F Innocenti, K Owzar, C Jiang, AB Sibley, D Niedzwiecki, MM Bertagnolli, PN Friedman, Y Furukawa, M Kubo, MJ Ratain, CD. Blanke, H-J Lenz, AP Venook, HL McLeod. European Cancer Congress (ESMO) Annual Meeting, (Sept 25-29, 2015, Vienna, Austria), accepted, oral presentation, abstr #2007. http://www.europecancercongress.org/Scientific-Programme/Abstract-search?abstractid=20000	10/1/05	3/1/12
C80701	Randomized phase II study of everolimus alone (E) versus everolimus plus bevacizumab (E+B) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors, CALGB 80701 (Alliance). MH Kulke, D Niedzwiecki, NR Foster, B Fruth, H Kennecke, EM Wolin, AP Venook. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <i>J Clin Oncol</i> 33:5s (suppl; abstr 4005), 2015. http://abstracts.asco.org/156/AbstView_156_150169.html	3/1/12	10/1/12

N0147	Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: results from NCCTG N0147 (Alliance). PP Singh, Q Shi, N Foster, A Grothey, AF Shields, FA Sinicrope, DJ Sargent, SR Alberts. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), poster session. <u>J Clin Oncol</u> 33:5s (suppl; abstr 3531), 2015. http://abstracts.asco.org/156/AbstView_156_144132.html	8/1/04	11/25/09
N0147	Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance). AI Phipps, Q Shi, PJ Limburg, GD Nelson, DJ Sargent, FA Sinicrope, E Chan, S Gill, RM Goldberg, M Kahlenberg, S Nair, AF.Shields, PA Newcomb, SR Alberts. American Society of Clinical Oncology Annual Meeting (May 29-June 2, 2015, Chicago, IL), oral presentation. <u>J Clin Oncol</u> 33:5s (suppl; abstr 1508), 2015. http://abstracts.asco.org/156/AbstView_156_152840.html	8/1/04	11/25/09
N1048	Compliance and interim results of a cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE embedded in the Alliance N1048 PROSPECT rectal cancer clinical trial. AC Dueck, SA Mitchell, LJ Rogak, B Ginos, SJ Sargent, Q Shi, JM Farma, C Eng, MD, C Crane, H Kennecke , AM O'Mara, L Minasian, D Schrag, E Basch. International Society for Quality of Life Research (ISOQOL) annual meeting (October 21-24, 2015, Vancouver, BC, CAN), oral presentation at the Cutting Edge Research Plenary Session. [See also SCQOL Committee]	4/15/12	n/a

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2014**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED/ACCEPTED (2014)			
S0713	Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study. P Mavroidis, D Giantsoudis, MJ Awan, J, CRN Rasch, JC Duppen, CR Thomas, Jr., P Okunieff, WE Jones, III, LA Kachnic, N Papanikolaou, CD Fuller, on Behalf of the Southwest Oncology Group Radiation Oncology Committee. <u>Radiotherapy and Oncology</u> 112(3):418-424, 2014. PMID24996454; PMC4258107 http://www.ncbi.nlm.nih.gov/pubmed/24996454	2/1/09	4/15/13
S0727	Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). PA Philip, B Goldman, RK Ramanathan, H-J Lenz, AM Lowy, RP Whitehead, W Zhang, S Iqbal, R Gaur, JK Benedetti, CD Blanke. <u>Cancer</u> 120(19):2980-2985, 2014. PMID:25041791; PMC4284963 http://www.ncbi.nlm.nih.gov/pubmed/25041791	3/10/08	9/1/10
S0941	SWOG S0941: a phase II study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. AB El-Khoueiry, C Rankin, AB Siegel, S Iqbal, I-Y Gong, KC Micetich, O Kayaleh, H Lenz, CD Blanke. <u>British Journal of Cancer</u> 110(4):882-887, 2014. PMID24423918; PMC3929880 http://www.ncbi.nlm.nih.gov/pubmed/24423918	4/1/510	9/5/11
S9304	Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (INT-0144; SWOG 9304). CM Ulrich, C Rankin, AT Toriola, K W Makar, Ö Altug-Teber, JK Benedetti, RS Holmes, SR Smalley, CD Blanke, H-J Lenz. <u>Cancer</u> 120(21):3329-3337, 2014. PMID:25041994; PMC4259283 http://www.ncbi.nlm.nih.gov/pubmed/25041994	3/1/94	8/1/00
C89803	Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). MA Fuchs, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, D Atienza, M Messino, H Kindler, A Venook, S Ogino, K Wu, WC Willett, EL Giovannucci, JA Meyerhardt. <u>PLOS ONE</u> 9(6):e99816, 2014. PMID24937507; PMC4061031 http://www.ncbi.nlm.nih.gov/pubmed/24937507	7/15/00	5/15/01

N0147	Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) inter-group trial N0147. J Huang, SG Nair, MR Mahoney, GD Nelson, AF Shields, E Chan, RM Goldberg, S Gill, MS Kahlenberg, JT Quesenberry, SN Thibodeau, TC Smyrk, A Grothey, FA Sinicrope, TA Webb, GH Farr, Jr, BA Pockaj, JL Berenberg, M Mooney, DJ Sargent, SR Alberts, for the Alliance for Clinical Trials in Oncology. <u>Clinical Colorectal Cancer</u> 13(2):100-109, 2014; PMID24512953; PMC4019685 http://www.ncbi.nlm.nih.gov/pubmed/24512953	8/1/04	11/25/09
NSAPB R-04	Capecitabine and oxaliplatin in the preoperative multi-modality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. MJ O'Connell, LH Colangelo, RW Beart, NJ Petrelli, CJ Allegra, S Sharif, HC Pitot, AF Shields, JC Landry, DP Ryan, DS Parda, M Mohiuddin, A Arora, LS Evans, N Bahary, GS Soori, J Eakle, JM Robertson, DF Moore Jr, MR Mullane, BT Marchello, PJ Ward, TF Wozniak, MS Roh, G Yothers, N Wolmark. <u>Journal of Clinical Oncology</u> 32(18):1927-34, 2014. PMID24799484; PMC4050205 http://www.ncbi.nlm.nih.gov/pubmed/24799484	4/15/06	8/16/10
Z9001	Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary KV Ballman, CR Antonescu, V Kolesnikova, RG Maki, PWT Pisters, ME Blackstein, CD Blanke, GD Demetri, MC Heinrich, M von Mehren, S Patel, MD McCarter, K Owzar, RP DeMatteo. <u>Journal of Clinical Oncology</u> 32(15):1563-1570, 2014. PMID24638003; PMC4026579 http://www.ncbi.nlm.nih.gov/pubmed/24638003	10/1/02	2/9/07
Multiple*	Historical controls for metastatic pancreatic cancer: benchmarks for planning and analyzing single arm phase II trials. PA Philip, K Chansky, L Rubinstein, M Leblanc, L Seymour, SP Ivy, SR Alberts, PJ Catalano, J Crowley. <u>Clinical Cancer Research</u> 20(16):4176-4185, 2014. PMID24914040; PMC4296727 *Multiple cooperative groups and multiple studies, including SWOG: S0107, S0205, S8916, S8933, S9100, S9135, S9313, S9629, S9924. http://www.ncbi.nlm.nih.gov/pubmed/24914040	n/a	n/a

GI ABSTRACTS ACCEPTED/PRESENTED/PUBLISHED (2014)

S0033	Long-term disease control of advanced gastrointestinal stromal tumors (GIST) with imatinib (IM): 10-year outcomes from SWOG phase III intergroup trial S0033. G Demetri, C Rankin, RS Benjamin, EC Borden, CW Ryan, DA Priebat, WD Tap, M von Mehren, ME Blackstein, MC Heinrich, RG Maki, CL Corless, JA Fletcher, K Owzar, CD Blanke. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), oral session; <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 10508), 2014. http://abstracts.asco.org/144/AbstView_144_134128.html	12/15/00	9/1/01
-------	--	----------	--------

S0809	SWOG S0809: A phase II trial of adjuvant capecitabine (cap)/ gemcitabine (gem) followed by concurrent capecitabine and radiotherapy in extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinoma (GBCA). E Ben-Josef, KA Guthrie, AB El-Khoueiry, CL Corless, MM Zalupski, AM Lowy, CR Thomas, SR Alberts, LA Dawson, K Micetich, MB Thomas, AB Siegel, CD Blanke. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), poster highlights session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 4030), 2014. http://abstracts.asco.org/144/AbstView_144_132530.html	12/1/08	10/1/12
S1005	A phase II study of MK-2206, an allosteric Inhibitor of AKT as second Line therapy for advanced gastric and gastro-esophageal junction (GEJ) cancer, a SWOG Cooperative Group Trial (S1005). RK Ramanathan, S McDonough, HF Kennecke, S Iqbal, J Baranda, TE Seery, H Lim, A Hezel, G Vaccaro, CD Blanke. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), general poster session. <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr 4041), 2014. http://abstracts.asco.org/144/AbstView_144_126933.html	1/1/11	5/1/13
C80405/SWOG	CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (uMCR). AP Venook, D Niedzwiecki, H-J Lenz, F Innocenti, MR Mahoney, BH O'Neil, JE Shaw, BN Polite, HS Hochster, JN Atkins, RM Goldberg, RJ Mayer, RL Schilsky, MM Bertagnolli, CD Blanke, Cancer and Leukemia Group B, SWOG and ECOG. American Society of Clinical Oncology Annual Meeting (May 30-June 3, 2014, Chicago, IL), scientific program plenary session (oral). <u>Journal of Clinical Oncology</u> 32:5s (suppl; abstr LBA3), 2014. http://abstracts.asco.org/144/AbstView_144_126013.html	10/1/05	3/1/12
C80405/SWOG	CALGB/SWOG C80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCR). H-J Lenz, D Niedzwiecki, F Innocenti, CD Blanke, MR Mahoney, BH O'Neil, JE Shaw, BN Polite, HS Hochster, JN Atkins, RM Goldberg, RJ Mayer, RL Schilsky, MM Bertagnolli, AP Venook. ESMO 2014 Congress (September 26-30, 2014, Madrid, Spain), LBA, oral presentation.	10/1/05	3/1/12
Multiple*	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: a prospective pooled analysis of > 11,500 patients from 6 Phase III trials of adjuvant therapy duration with FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) for stage III colon cancer. D Sargent, J Paul, A Sobrero, T André, AF Shields, T Yoshino, I Souglakos, T Iveson, R Labianca, J Taieb, JA Meyerhardt, A Ohtsu, A Grothey for the IDEA Steering Committee. ESMO 2014 Congress (September 26-30, 2014, Madrid, Spain), trials in progress poster presentation. *Pooled analysis includes C80702.		

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2013**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED (2013)			
S0030	Higher area under the curve and reduced capecitabine clearance in elderly patients with advanced colorectal cancer (SWOG 0030). S Louie, B Ely, H Lenz, K Albain, C Gotay, D Coleman, D Raghavan, A Shields, P Gold, CD Blanke. <u>British Journal of Cancer</u> , 109(7):1744-1749, 2013. PMID:24022189; PMC3790171. http://www.ncbi.nlm.nih.gov/pubmed/24022189	2/1/03	2/1/05
S9008	Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. MA Gordon, H Gundacker, JS Macdonald, J Baranda, W Levin, C Fenoglio-Preiser, N Wick, CD Blanke, J Benedetti, W Elatre, P Weng, H Lenz, MF Press. <u>Annals of Oncology</u> 24(7)1754-1761, 2013. PMID23524864; PMC3690906 http://www.ncbi.nlm.nih.gov/pubmed/?term=gordon+ma+HER2	8/1/91	7/15/98
A021101	Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. MHG Katz, R Marsh, JM Herman, Q Shi, E Collison, AP Venook, HL Kindler, SR Alberts, P Philip, AM Lowy, PWT Pisters, MC Posner, JD Berlin, SA Ahmad. <u>Annals of Surgical Oncology</u> 20(8):2787-2795, 2013. PMID23435609; (review article not within in scope of Public Access Policy) http://www.ncbi.nlm.nih.gov/pubmed/23435609	5/15/13	n/a
C80702/multiple	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: trial design and current status. T Andre, T Iveson, R Labianca, JA Meyerhardt, I Souglakos, T Yoshino, J Paul, A Sobrero, J Taieb, AF Shields, A Ohtsu, A Grothey, DJ Sargent and for the IDEA Steering Committee. <u>Current Colorectal Cancer Reports</u> 9:261-269, 2013. PMID24032000; PMC3766516 http://www.ncbi.nlm.nih.gov/pubmed/24032000	8/15/10	n/a
C89803	Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: findings from CALGB 89803/Alliance. J Jeon, K Sato, D Niedzwiecki, X Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, DS Wigler, D Atienza, M Messino, H Kindler, A Venook, CS Fuchs, JA Meyerhardt. <u>Cancer Clinical Colorectal Cancer</u> 12(4):233-238, 2013. PMID24035029; PMC3818492 http://www.ncbi.nlm.nih.gov/pubmed/24035029	7/15/00	5/15/01

C89803	Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer: data from Intergroup Trial CALGB 89803 (Alliance). S Ogino, X Liao, Y Imamura, M Yamauchi, NJ McCleary, K Ng, D Niedzwiecki, L Saltz, RJ Mayer, R Whittom, A Hantel, AB Benson, RB Mowat, D Spiegelman, RM Goldberg, MM Bertagnolli, JA Meyerhardt, CS Fuchs. <u>Journal of the National Cancer Institute</u> 105(23):1789-1798, 2013. PMID24231454; PMC384898 http://www.ncbi.nlm.nih.gov/pubmed/24231454	7/15/00	5/15/01
C89803/ C80405	Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. K Van Loon, D Niedzwiecki, AP Venook, C Fuchs, C Blanke, L Saltz, RM Goldberg, JA Meyerhardt. <u>Clinical Colorectal Cancer</u> 12(2):95-102, 2013. PMID23317558; PMC3790266 http://www.ncbi.nlm.nih.gov/pubmed/23317558	7/15/00 10/1/05	5/15/01 3/1/12
R9811	Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. LL Gunderson, J Moughan, JA Ajani, JE Pedersen, KA Winter, AB Benson III, CR Thomas Jr, RJ Mayer, MG Haddock, TA Rich, CG Willett. <u>International Journal of Radiation Oncology, Biology, Physics</u> 87(4):638-645, 2013. PMID24035327; PMC3938865 http://www.ncbi.nlm.nih.gov/pubmed/24035327		
Z9000	Long-term results of adjuvant mesylate in localized, high-risk, primary gastrointestinal stromal tumor ACOSOG Z9000 (Alliance) intergroup phase 2 trial. R DeMatteo, K Ballman, C Antonescu, C Corless, V Kolesnikova, M von Mehren, M McCarter, J Norton, R Maki, P Pisters, G Demetri, M Brennan, K Awzar on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology. <u>Annals of Surgery</u> 258(3):422-429, 2013. PMID23860199; PMC pending http://www.ncbi.nlm.nih.gov/pubmed/23860199	10/1/02	9/30/03
Multiple*	Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database. Q Shi, T Andre, A Grothey, G Yothers, SR Hamilton, BM Bot, DG Haller, E Van Cutsem, C Twelves, JK Benedetti, MJ O'Connell, DJ Sargent. <u>Journal of Clinical Oncology</u> , 31(29):3656-3663, 2013. PMID23980089; PMC3804289 *Pooled database analysis. http://www.ncbi.nlm.nih.gov/pubmed/23980089	n/a	n/a
Multiple*	The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database. W Cheung, Q Shi, M O'Connell, J Cassidy, CD Blanke, DJ Kerr, J Meyers, E Van Cutsem, SR Alberts, G Yothers, D Sargent. <u>Clinical Colorectal Cancer</u> 12(3):179-187, 2013. *Pooled database analysis. PMID23810482; PMC3760214 http://www.ncbi.nlm.nih.gov/pubmed/23810482	n/a	n/a

GI ABSTRACTS PRESENTED/PUBLISHED (2013)

S0820	Challenges of recruiting native Alaskans to a nationwide colorectal cancer prevention study. E Cook, K Anderson, J Zell, P Brown. American Society of Preventive Oncology 37th Annual Meeting (March 9-12, 2013 Memphis, TN), poster presentation. (also Prevention Committee) http://www.aspo.org/files/2013/PROGRAMWebsiteMarch3.pdf	pending	n/a
S1115	SWOG S1115: randomized phase II clinical trial of AZD6244 8/15/12 hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in patients with metastatic pancreatic cancer after prior chemotherapy. V Chung, S McDonough, PA Philip, D Backlund Cardin, AM Lowy, JK Benedetti, CD Blanke. American Society of Clinical Oncology Annual Meeting (May 31-June 4, 2013, Chicago, IL), "Trials in Progress," general poster session. <u>Journal of Clinical Oncology</u> 31(suppl; abstr TPS4145), 2013. http://abstracts2.asco.org/AbstView_132_111210.html		n/a

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2012**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED
GI MANUSCRIPTS PUBLISHED (2012)			
S0414	Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase II study of the SWOG (S0414). M Tomblyn, B Goldman, C Thomas, J Benedetti, H Lenz, V Mehta, T Beeker, P Gold, Abbruzzese JL, C Blanke. <i>Journal of Thoracic Oncology</i> 7(5):906-992, 2012. PMID22481235; PMC3382003 http://www.ncbi.nlm.nih.gov/pubmed/22481235	5/1/05	9/1/07
S0514	SWOG 0514: A phase II study of sorafenib in patients with resectable or metastatic gallbladder carcinoma and cholangiocarcinoma. PMID21748296. A El-Khoueiry, C Rankin, E Ben-Josef, HJ Lenz, PJ Gold, RD Hamilton, R Govindarajan, C Eng, CD Blanke. <i>Investigational New Drugs</i> , 30(4):1646-1651, 2012. PMID21748296; PMC3490705 http://www.ncbi.nlm.nih.gov/pubmed/21748296	10/01/05	01/01/07
S9008	Updated analysis of SWOG-directed Intergroup study 0116: a phase III trial of adjuvant radio-chemotherapy versus observation following curative gastric resection (CALGB-9195; ECOG-6290; NCCTG-90-41; RTOG 9018 and SWOG-9008. S Smalley, J Benedetti, C Blanke, D Haller, S Hundahl, N Estes, J Ajani, L Gunderson, B Goldman, J Martenson, J Jessup, G Stemmerman, JS Macdonald. <i>Journal of Clinical Oncology</i> , 30(19): 2327-2333, 2012. PMID2258569; PMC Journal – In Process. http://www.ncbi.nlm.nih.gov/pubmed/22585691	8/1/91	7/15/98
C89803	Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. JA Meyerhardt, K Sato, D Niedzwiecki, C Ye, LB Saltz, RJ Mayer, RB Mowat, R Whittom, A Hantel, A Benson, DS Wigler, A Venook, CS Fuchs. <i>Journal of the National Cancer Institute</i> 104(22):1702-1711, 2012. PMID23136358; PMC3502194 http://www.ncbi.nlm.nih.gov/pubmed/23136358	7/15/00	5/15/01
C89803	Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. S Ogino, K Shima, J Meyerhardt, NJ McCleary, K Ng, L Saltz, R Mayer, P Schaefer, R Whittom, A Hantel, A Benson, D Spiegelman, R Goldberg, M Bertagnoli, C Fuchs. <i>Clinical Cancer Research</i> 18(3):890-900, 2012. PMID22147942; PMC3271172 http://www.ncbi.nlm.nih.gov/pubmed/22147942	7/15/00	5/15/01

N0147	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. SR Alberts, DJ Sargent, S Nair, MR Mahoney, M Mooney, SN Thibodeau, TC Smyrk, FA Sinicrope, E Chan, S Gill, MS Kahlenberg, AF Shields, JT Quesenberry, TA Webb, GH Farr, Jr, BA Pockaj, A Grothey, RM Goldberg. <u>Journal of the American Medical Association</u> 307(13):1383-1393, 2012. PMID22474202;PMC3442260 http://www.ncbi.nlm.nih.gov/pubmed/22474202	8/1/04	11/25/09
R9704	Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704 - a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. RA Abrams, KA Winter, WF Regine, H Safran, JP Hoffman, R Lustig, AA Konski, AB Benson, JS Macdonald, TA Rich, CG Willett. <u>International Journal of Radiation Oncology Biology Physics</u> , 82(2):809-816, 2012. PMID21277694; PMC3133855 http://www.ncbi.nlm.nih.gov/pubmed/21277694	5/1/99	7/6/02
R9704	Five year results of US Intergroup/RTOG 9704 with post-operative CA 19-9 $\leq$ 90 U/mL and comparison to the CONKO-001 trial. AC Berger, K Winter, JP Hoffman, WF Regine, RA Abrams, H Safran, GM Freedman, AB Benson, J Macdonald, CG Willett. <u>International Journal of Radiation Oncology, Biology & Physics</u> 84(3):e291-297, 2012. PMID22682806 http://www.ncbi.nlm.nih.gov/pubmed/22682806	5/1/99	7/6/02
R9811	Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. LL Gunderson, KA Winter, JA Ajani, JE Pedersen, J Moughan, AB Benson, CR Thomas, RJ Mayer, MG Haddock, TA Rich, CG Willett. <u>Journal of Clinical Oncology</u> 30(35):4344-4351, 2012. PMID23150707; PMC3515768 http://www.ncbi.nlm.nih.gov/pubmed/23150707	3/1/01	6/27/05
Z9000	Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. MD McCarter, CR Antonescu, KV Ballman, RG Maki, PWT Pisters, GD Demetri, CD Blanke, M von Mehren, MF Brennan, L McCall, D Ota, RP DeMatteo. <u>Journal of the American College of Surgeons</u> , 215(1):53-59, 2012. PMID22726733; PMC3383609 http://www.ncbi.nlm.nih.gov/pubmed/22726733	10/1/02	9/30/03

GI ABSTRACTS PUBLISHED/PRESENTED (2012)

S0205	Use of EGF A61G polymorphism to predict overall survival of gemcitabine bolus cetuximab versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (SWOG 0205). M Labonte, B Goldman, W Zhang, CD Blanke, PA Philip, R Wong, EM O'Reilly, JK Benedetti, HJ Lenz. ASCO 2012 GI Cancers Symposium (June 19-21), 2012, San Francisco, CA), poster presentation; <u>Journal of Clinical Oncology</u> 30: (suppl.4; abstr 203), 2012. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87914	1/1/04	4/1/06
-------	---	--------	--------

S0727	Phase I and randomized phase II trial of gemcitabine, erlotinib, 3/108 and IMC-A12 cixutumumab) versus gemcitabine plus erlotinib as first line treatment in patients with metastatic pancreatic cancer (SWOG S0727. PA Philip, B Goldman, R Ramanathan, H Lenz, A Lowy, R Whitehead, S Iqbal, R Gaur, J Benedetti, CD Blanke. American Society of Clinical Oncology 2012 GI Cancers Symposium (January 19-21, 2012, San Francisco, CA) poster presentation; <u>J Clin Oncol</u> 30, 2012:(suppl 4; abstr 198). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=115&abstractID=87986	9/1/10
S0727	Dual blockade of epidermal growth factor receptor (EGFR) 3/108 and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib. PA Philip, B Goldman, R Ramanathan, H Lenz, A Lowy, R Whitehead, S Iqbal, R Gaur, J Benedetti, CD Blanke. <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4019). http://abstract.asco.org/AbstView_114_98448.html	9/1/10
S0941	SWOG 0941: A phase II study of sorafenib and erlotinib in 4/15/10 patients (pts) with advanced gallbladder cancer or cholangio- carcinoma. A El-Khoueiry, C Rankin, S Iqbal, K Micetich, O Kayaleh, H Lenz, C Blanke. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4113). http://abstract.asco.org/AbstView_114_100314.html	9/15/11
S9008	Assessment of HER2 gene amplification in adenocarcino- 8/1/91 mas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. MA Gordon, H Gundacker, J Benedetti, J Macdonald, J Baranda, W Levin, N Wick, C Blanke, W Elatre, P Weng, J-Y Zhou, H Lenz, M Press. American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion; <u>J Clin Oncol</u> 30, 2012 (suppl; abstr 4010). http://abstract.asco.org/AbstView_114_92136.html	7/15/98
NSABP R-04	Comparative effectiveness of sphincter-sparing surgery 7/1/06 (SSS) versus abdomino-perineal resection (APR) in rectal cancer: Patient-reported outcomes (PROs) from NSABP R-04. PA Ganz, SH Lopa, G Yothers, CY Ko, A Arora, JN Atkins, N Bahary, GS Soori, JM Robertson, JF Eakle, BT Marchello, TF Wozniak, N Wolmark <u>J Clin Oncol</u> 30: (suppl; abstr 3545), 2012. http://meetinglibrary.asco.org/content/94535-114 (also under SCQOL Committee)	11/6/09
NSABP R-04	Patient-reported outcomes (PROs) comparison of 5-FU and 7/1/06 capecitabine (cape) with concurrent radiotherapy (RT) for neoadjuvant treatment of rectal cancer: Results of NSABP R-04. G Yothers, PA Ganz, SH Lopa, C Y Ko, DL Wickerham, N Wolmark <u>J Clin Oncol</u> 30:(suppl 4; abstr 391), 2012. http://meetinglibrary.asco.org/content/88085-115 (also under SCQOL Committee)	11/6/09

*R9704

Predictive markers of gemcitabine treatment response in
pancreas cancer: a pharmacogenomics pathway approach.
J Farrell, J Wong, J Moughan, W Regine, P Schaefer, A Benson
J Macdonald, X Liu, Y Yen, R Lai, Z Zheng, G Bepler, H Elsaleh.
Digestive Disease Week 2012 Annual Meeting (May 19-22, 2012,
San Diego, CA) oral presentation (plenary session);
Gastroenterology Vol. 142, Issue 5, Supplement 1, page
S-113, 2012.
[http://download.journals.elsevierhealth.com/pdfs/journals/0016-
5085/PIIS0016508512604247.pdf](http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508512604247.pdf)

5/1/99

7/6/02

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2011**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
GI MANUSCRIPTS PUBLISHED (2011)			
S0202	A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. S Iqbal, C Rankin, HJ Lenz, PJ Gold, S Ahmad, A El-Khoueiry, M Messino, R Holcombe, CD Blanke. <u>Cancer Chemotherapy and Pharmacology</u> , 68(6):1595-1602, 2011 . PMID21556747; PMC3519425 http://www.ncbi.nlm.nih.gov/pubmed/21556747	9/1/03	4/1/05
S0356	S0356: A phase II clinical and prospective molecular Trial with oxaliplatin, 5-fluorouracil, and external-beam radiation therapy prior to surgery for patients with esophageal adenocarcinoma. LP Leichman, B Goldman, C Thomas, K Billingsley, C Corless, J Benedetti, HJ Lenz, S Iqbal, P Gold, CD Blanke. <u>Journal of Clinical Oncology</u> 29(34):4555-4560, 2011. PMID22025151; PMC3236655 http://www.ncbi.nlm.nih.gov/pubmed/22025151	9/15/04	8/1/08
S0413	Southwest Oncology Group study S0413: a phase II Trial of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer. S Iqbal, B Goldman, C Fenoglio-Preiser, HJ Lenz, W Zhang, KD Dannenberg, S Shibata, C Blanke. Not accepted by <u>Journal of Clinical Oncology</u> ; <u>Annals of Oncology</u> 22(12):2610-2615, 2011. PMID21415234; PMC3221514 http://www.ncbi.nlm.nih.gov/pubmed/?term=iqbal+s+S0413	12/15/04	5/15/06
S0713	Prospective randomized double-blind pilot study of site-specific consensus atlas implementation for rectal cancer target volume delineation in the cooperative group setting. CD Fuller, J Nijkamp, JC Duppen, CR Rasch, CR Thomas, Jr, SJ Wang, P Okunieff, WE Jones, D Baseman, S Patel, CG Demandante, AM Harris, BD Smith, AW Katz, C McGann, JL Harper, DT Chang, S Smalley, DT Marshall, KA Goodman, N Papanikolaou, LA Kachnic. <u>International Journal of Radiation Oncology, Biology & Physics</u> 79(2):481-489, 2011. PMID20400244; PMC2929319 http://www.ncbi.nlm.nih.gov/pubmed/20400244	2/1/09	n/a
S9008	Gastric Cancer: Nagoya is not New York. JS Macdonald. <u>Journal of Clinical Oncology</u> 29(33):4348-4350, 2011. PMID 22010021; Editorials not within scope of Public Access Policy http://www.ncbi.nlm.nih.gov/pubmed/22010021	8/1/91	7/15/98

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S9041	Colorectal chemoprevention pilot study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. D Chu, M Hussey, D Alberts, F Meyskens, C Fenoglio-Preisser, S Rivkin, G Mills, J Giguere, C Blanke, G Goodman. <u>Clinical Colorectal Cancer</u> , 10(4):310-316, 2011 PMID21782524; NIHMS326411 http://www.ncbi.nlm.nih.gov/pubmed/21782524	2/1/93	4/15/99
S9415	Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. G Yothers, DJ Sargent, N Wolmark, RM Goldberg, MJ O'Connell, JK Benedetti, LB Saltz, JJ Dignam, AW Blackstock. <u>Journal of the National Cancer Institute</u> 103(20):1498-1506, 2011. PMID21997132; PMC3196480. http://www.ncbi.nlm.nih.gov/pubmed/21997132	2/1/94	12/15/99
C89803	Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. K Ng, S Ogino, JA Meyerhardt, JA Chan, AT Chan, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, AB Benson, PL Schaefer, R Whittom, A Hantel, RM Goldberg, MM Bertagnolli, AP Venook, CS Fuchs. <u>Journal of the National Cancer Institute</u> 103(20):1540-1551, 2011. PMID:21849660; PMC3196479 http://www.ncbi.nlm.nih.gov/pubmed/21849660	7/15/00	5/15/01
R9704	Fluorouracil-based chemoradiation with either Gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704. WF Regine, KA Winter, R Abrams, H Safran, JP Hoffman, A Konski, AB Benson, JS Macdonald, TA Rich, CG Willett. <u>Annals of Surgical Oncology</u> 18(5):1319-1326, 2011. PMID21499862 No PMCID or NHMSID available. Please note that this is a RTOG cooperative group submission. SWOG investigators endorsed/participated in the study which was recognized with authorship for SWOG member, JS Macdonald) http://www.ncbi.nlm.nih.gov/pubmed/21499862	5/1/99	7/6/02
R9704	The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. TN Showalter, AC Berger, WF Regine, RA Abrams, H Safran, JP Hoffman, AB Benson, JS Macdonald, CG Willett. <u>International Journal of Radiation Oncology Biology Physics</u> 81(5): 1328-1335, 2011. PMID20934270; PMC3038247 http://www.ncbi.nlm.nih.gov/pubmed/20934270	5/1/99	7/6/02

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED (2011)			
*S0033	Long-term survival on S0033: a phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs). CD Blanke, C Rankin, RS Benjamin, AK Raymond, MC Heinrich, CDM Fletcher, JJ Crowley, EC Borden, GD Demetri, LH Baker. European Society for Medical Oncology 2011 Meeting (Sept. 23-27, 2011, Stockholm, Sweden), oral presentation.	12/15/00	9/1/01
S0033	Long-terms follow-up of SWOG S0033, a phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). LH Baker, CJ Rankin, CD Blanke, GD Demetri, JJ Crowley, RS Benjamin. Connective Tissue Oncology Society Annual Meeting (10/26-29/11, Chicago, IL), oral presentation.	12/15/00	9/1/01
S0356	Association of excision repair cross-complementation group 1(ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative study (SWOG 0356).P Bohanes, B Goldman, J Benedetti, C Blanke , L Leichman , S Iqbal, C Thomas, C Corless, P Gold, H Lenz. American Society of Clinical Oncology GI 2011 Symposium, oral presentation; <u>Journal of Clinical Oncology</u> 29:(suppl 4: abstr 2), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=103&abstractID=71402	9/15/04	8/1/08
S0356	Association of excision repair cross-complementation Group 1 (ERCC1) gene expression (GE) with outcome in stage II-III esophageal adenocarcinoma (EA) patients treated with preoperative platinum-based chemoradiation (CRT) in a phase II cooperative group study(SWOG S0356). PO Bohanes, BH Goldman, LP Leichman, CD Blanke, S Iqbal, CR Thomas, CL Corless, KG Billingsley, KD Danenberg, W Zhang, JK Benedetti, PJ Gold, H Lenz. ASCO 2011 meeting, poster discussion. <u>Journal of Clinical Oncology</u> 29:(suppl; abstr 4023), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82045	9/15/04	8/1/08
S9304	The final results of the SWOG S9304 phase III Intergroup trial's pharmacogenetic analysis: association of polymorphisms with survival and toxicity in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation (RT). P Wilson, P Bohanes, C Rankin, J Benedetti, C Ulrich, S Smalley, D Makar, W Zhang, T Winder, Y Ning, A Gerger, L Benhaim, R El-Khoueiry, M Labonte, C Blanke, H Lenz. ASCO 2011 annual meeting (June 4-8, 2011, Chicago, IL), poster presentation; <u>Journal of Clinical Oncology</u> 29:(suppl;abstr 3542), 2011. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84455	3/1/94	8/1/00

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
C80101	Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. C Fuchs, JE Tepper, D Niedzwiecki, D Hollis, HJ Mamon, R Swanson, DG Haller, T Dragovich, SR Alberts, GA Bjarnason, CG Willett PC Enzinger, RM Goldberg, AP Venook, RJ Mayer. <u>Journal of Clinical Oncology</u> 29:2011 (suppl; abstr 4003); ASCO annual meeting, oral presentation. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=82318	3/15/03	5/29/09

**SWOG
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2010**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
GI MANUSCRIPTS PUBLISHED (2010)			
S9415/multiple	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. A de Gramont, J Hubbard, Q Shi, MJ O'Connell, M Buyse, J Benedetti, B Bot, C O'Callaghan, G Yothers, RM Goldberg, CD Blanke, A Benson, Q Denz, SR Alberts, T Andre, N Wolmark, A Grothey, D Sargent. <u>Journal of Clinical Oncology</u> 28(3):460-465, 2010. PMC2815708;PMID20008641 http://www.ncbi.nlm.nih.gov/pubmed/20008641	12/1/94	12/15/99
S9511	A Southwest Oncology Group phase II study of trimetrexate, 5FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. CD Blanke, K Chansky, KL Christman, SA Hundahl, BF Issell, PJ Van Veldhuizen Jr, GT Budd, JL Abbruzzese, JS Macdonald. <u>American Journal of Clinical Oncology</u> . 33(2):117-120, 2010.PMID19770625; PMC2967385 http://www.ncbi.nlm.nih.gov/pubmed/19770625	1/15/97	11/15/98
S0033	Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. Gastrointestinal Tumor Meta-Analysis Group – MetaGIST (M. van Glabbeke, J. Verweij, J-Y. Blay, M. Debiec-Rychter, G.D. Demetri, M.C. Heinrich, E.C. Borden, B.G. Redman, C.D. Blanke, C. Rankin, J. Crowley, P. Casali, M. von Mehren, C. Fletcher, J. Fletcher, K. Owzar, J. Zalcberg, J. Simes, V. Bramwell-Wesley). <u>Journal of Clinical Oncology</u> 28(7):1247-1253, 2010. PMID30124181; PMC2834472 http://www.ncbi.nlm.nih.gov/pubmed?term=metaGIST%20imatinib	12/15/00	9/1/01
S0205	Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. PA Philip, J Benedetti, CL Corless, R Wong, EM O'Reilly, PJ Flynn, KM Rowland, JN Atkins, BC Mirtsching, SE Rivkin, AA Khorana, B Goldman, CM Fenoglio-Preiser, JL Abbruzzese, CD Blanke. Not accepted by <u>New England Journal of Medicine</u> ; <u>Journal of Clinical Oncology</u> 28(22):3605-3610, 2010. PMID20606093;PMC2917315 http://www.ncbi.nlm.nih.gov/pubmed/20606093	1/1/04	4/1/06

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0205	Pain and emotional well-being outcomes in Southwest Oncology Group 0205: a phase II randomized, open Label study comparing gemcitabine plus cetuximab (IMC-225) versus gemcitabine as first-line therapy of patients with advanced pancreas cancer. CM Moinpour, N Vaught, B Goldman, M Redman, PA Philip, JN Atkins, TE Seay, PJ Flynn, EM O'Reilly, JK Benedetti, CD Blanke. <u>Journal of Clinical Oncology</u> 28(22):3611-3616, 2010 PMID: 20606094; PMC2917316 (also listed under Symptom Control & Quality of Life Committee) http://www.ncbi.nlm.nih.gov/pubmed/20606094	1/1/04	4/1/06
S0415	Cetuximab as second-line therapy in patients with Metastatic esophageal cancer: a phase II Southwest Oncology Group study (S0415). PJ Gold, B Goldman, S Iqbal, LP Leichman, W Zhang, JH Lenz, CD Blanke. Not accepted by <u>Journal of Clinical Oncology</u> , 11/09; not accepted by <u>Annals of Oncology</u> 1/19/10; <u>Journal of Thoracic Oncology</u> 5(9):1472-1476, 2010. PMID:20631636; PMC2928397 http://www.ncbi.nlm.nih.gov/pubmed?term=dorff%20t%20monoclonal	10/15/04	1/1/07
C89803	Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B89803. N McCleary, D Niedzwiecki, D Hollis, L Saltz, P Schaefer, R Whittom, A Hantel, A Benson, R Goldberg, JA Meyerhardt. <u>Cancer</u> 116(4):957-966, 2010. PMC2884300; PMID 20052723 http://www.ncbi.nlm.nih.gov/pubmed?term=Mccleary%20n%20impact%20of%20smoking	7/15/00	5/15/01
C89803	Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. K Ng, JA Meyerhardt, JA Chan, D Niedzwiecki, DR Hollis, LB Saltz, RJ Mayer, AB Benson, PL Schaefer, R Whittom, A Hantel, RM Goldberg, C Fuchs. <u>Journal of Clinical Oncology</u> , 28(29):4354-4363, 2010 . PMID20805450; PMC2954134 http://www.ncbi.nlm.nih.gov/pubmed?term=ng%20k%20multivitamin	7/15/00	5/15/01

ABSTRACTS PUBLISHED/PRESENTED (2010)

*S0356	A updated report on the pathologic complete response response and survival outcome of Southwest Oncology Group (SWOG S0356): A phase II trial of oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA) with molecular correlates. L Leichman, B Goldman, C Thomas, K Billingsley, C Corless, H Lenz, S Iqbal, J Benedetti, P Gold, C Blanke. American Society of Therapeutic Radiation Oncologists (ASTRO) Annual Meeting, 2010, oral presentation; <u>Int J Radiation Oncol Biol Physics</u> 78(3):suppl., abst.#61, S28-29, 2010. http://www.sciencedirect.com/science/article/pii/S0360301610010801	9/15/04	8/1/08
--------	--	---------	--------

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0414	Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy (TRT) as definitive treatment for locally advanced, unresectable esophageal cancer (Ec): a SWOG (S0414) phase II trial. CR Thomas, BH Goldman, JK Benedetti, H Lenz, T Beeker, JL Abbruzzese, C Blanke. Poster presentation, 2010 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (January 22-24, 2010, Orlando, FL), abstr. #72. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=109	5/1/05	9/1/07
S0727	A randomized phase II trial of combination gemcitabine + erlotinib + IMC-A12 (cixutumumab) vs. gemcitabine + erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer: Southwest Oncology Group study (SWOG S0727). PA Philip, B Goldman, RK Ramanathan, HJ Lenz, AM Lowy, RP Whitehead, S Iqbal, V Chung, JK Benedetti, CD Blanke. "Trials in Progress" poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> , 28:7s (suppl; abstr TPS223), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50948	3/1/08	n/a
S0727	Phase I trial of combination gemcitabine, erlotinib (NSC-718781) and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. PA Philip, B Goldman, RK Ramanathan, H-J Lenz, AM Lowy, RP Whitehead, S Iqbal, V Chung, JK Benedetti, CD Blanke. Poster presentation, 2010 American Society for Clinical Oncology Gastrointestinal Cancers Symposium, abstr #233. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=72&abstractID=2202	3/1/08	n/a
S9304	Association of Intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation in a phase III intergroup trial (SWOG 9304). R Ladner, CM Ulrich, C Rankin, K Danenberg, P Danenberg, S Smalley, K Makar, J Benedetti, CD Blanke, HJ Lenz. Poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s (suppl; abstr 8502), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=44511	3/1/94	8/1/00
S9415/Multiple	Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 vs. 1996-2007: impact on recurrent rate, time from recurrence to death (TRD) and overall survival (OS); findings from the ACCENT dataset. T Andre, Q Shi, GA Yothers, BM Bot, DG Haller, E Van Cutsem, J Cassidy, J Benedetti, M O'Connell, DJ Sargent. <u>Journal of Clinical Oncology</u> 28:15s (suppl; abstr 3616), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=50544	12/1/94	12/15/99

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
E2204	ECOG 2204: An intergroup phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced pancreatic cancer (CAP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT 00002633). J Berlin, PJ Catalano, Y Feng, AM Lowy, AW Blackstock, PA Philip, RR McWilliams, J Abbruzzese, AB Benson. <u>Journal of Clinical Oncology</u> 28:7s (suppl; abstr 4024), 2010 (poster presentation). http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54565	10/15/06	1/9/08
E2205	A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab followed by post-operative docetaxel cetuximab in patients with operable adenocarcinoma of the esophagus. MK Gibson, L Kleinberg, C Staley, P Catalano, F Song, MF Mulcahy, LP Leichman, AB Benson. Poster presentation, American Society for Clinical Oncology, 2010 Annual Meeting; <u>Journal of Clinical Oncology</u> 28:7s(suppl; abstr 4064), 2010. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=54089		

SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
GASTROINTESTINAL COMMITTEE
2009

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
GASTROINTESTINAL MANUSCRIPTS PUBLISHED (2009)			
S0336 (2520)	Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study. RP Whitehead, C Rankin, PMG Hoff, PJ Gold, KG Billingsley, RA Chapman, L Wong, JH Ward, JL Abbruzzese, CD Blanke. <u>Investigational New Drugs</u> , 27(5):469-75, 2009. PMID18941712 http://www.ncbi.nlm.nih.gov/pubmed/18941712	4/15/04	9/1/05
C89803	KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. S Ogino, JA Meyerhardt, N Irahara, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, P Schaefer, R Whittom, A Hantel, A Benson, RM Goldberg, M Bertagnolli, CS Fuchs. <u>Clinical Cancer Research</u> 15(23):7322-7329, 2009. PMC2787689; PMID19934290 http://www.ncbi.nlm.nih.gov/pubmed/19934290	7/15/00	5/15/01
N9841 (2592)	A randomized phase III non-inferiority trial of irinotecan (CPT-11) versus oxaliplatin (OXAL)/5-fluorouracil (5-FU)/leucovorin (CF) in patients with advanced colorectal carcinoma previously treated with 5-FU, N9841. GP Kim, HC Pitot, KM Rowland, DJ Sargent, MR Mahoney, PA Philip, E Mitchell, GS Soori, TR Fitch, RM Goldberg, SR Alberts. <u>Journal of Clinical Oncology</u> , 27(17):2848-2854, 2009. PMC2698019; PMID: 19380443 http://www.ncbi.nlm.nih.gov/pubmed?term=Kim%20GP%20N9841	4/1/00	12/17/03
R9704	Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. JJ Farrell, H Elsaleh, M Garcia, R Lai, A Ammar, WF Regine, R Abrams, AB Benson, J Macdonald, CE Cass, AP Dicker, JR Mackey. PMID18992248 http://www.ncbi.nlm.nih.gov/pubmed/18992248	5/1/99	7/6/02
R9811	US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. JA Ajani, KA Winter, LL Gunderson, J Pederson, AB Benson, CR Thomas, RJ Mayer, MG Haddock, TA Rich, CG Willett. <u>Journal of Clinical Oncology</u> 27(7):1116-1121, 2009. PMID19138424 http://www.ncbi.nlm.nih.gov/pubmed/19139424	1/15/04	2/12/08
Multiple	Consensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatment. P Philip, M Mooney, D Jaffe, G Eckhardt, M Moore, N Meropol, L Emens, E O'Reilly, M Korc, L Ellis, J Benedetti, R Rothenberg, C Willett, M Tempero, A Lowy, J Abbruzzese, D Simeone, S Hingorani, J Berlin, J Tepper. <u>Journal of Clinical Oncology</u> 27(33):5660-5669, 2009. PMID: 19858397 http://www.ncbi.nlm.nih.gov/pubmed/19858397	n/a	n/a

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED (2009)			
S0356 (2633)	Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). L Leichman, B Goldman, C Thomas, K Billingsley, C Corless, HJ Lenz, S Iqbal, J Benedetti, P Gold, CD Blanke. <u>Journal of Clinical Oncology</u> 27:15s, abst. #4513, 2009. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34059	9/15/04	8/1/08
S0414 (2691)	Cetuximab (C225) plus cisplatin (CDDP), irinotecan (CPT11) and thoracic radiotherapy (TRT as definitive treatment for locally advanced, clinically unresectable esophageal cancer (EC): a Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0414). CR Thomas, BH Goldman, JK Benedetti, HJ Lenz, T Baker, L Hammond-Thelin, VK Mehta, CM Fenoglio-Preiser, JL Abbruzzese, CD Blanke. Accepted for poster discussion, ASTRO 2009 Annual Meeting (November 1-5, 2009), International J Radiation Oncol Biology & Physics 75(3)suppl.abst #1094, S168, 2009. http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T7X-4XC93XM-F5&_user=99318&_coverDate=11%2F01%2F2009&_rdoc=369&_fmt=high&_orig=browse&_origin=browse&_zone=rslt_srch=doc-info(%23toc%235070%232009%23999249996.8998%231528301%23FLA%23display%23Volume)&_cdi=5070&_sort=display%23Volume)&_or=&_view=c&_ct=1627&_acct=C000007678&_version=1&_urlVersion=0&_userid=99318&md5=7d65881436acec89bb1eae8&searchtype=a	5/1/05	9/1/07
S9008 (2638)	Chemoradiation of resected gastric cancer: a 10 year followup of INT0116 (SWOG 9008). J Macdonald, J Benedetti, S Smalley, D Haller, S Hundahl, J Jessup, J Ajani, L Gunderson, B Goldwin, J Martenson. <u>Journal of Clinical Oncology</u> 27:15s, abst. #4515, 2009. http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31673	8/1/91	7/15/98

*presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2008**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
S0033 (2468)	Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. CD Blanke, C Rankin, GD Demetri, CW Ryan, M von Mehren, RS Benjamin, AK Raymond, VH Bramwell, LH Baker, RG Maki, JR Hecht, MC Heinrich, CD Fletcher, JJ Crowley, EC Borden. <u>Journal of Clinical Oncology</u> 26(4):626-632, 2008. PMID: 18235122	GI	12/15/00	9/1/01
S0033 (2656)	Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 study by Cancer and Leukemia Group B and Southwest Oncology Group. MC Heinrich, K Owzar, CL Corless, D Hollis, EC Borden, CD Fletcher, CW Ryan, M von Mehren, CD Blanke, C Rankin, RS Benjamin, VH Bramwell, GD Demetri, MM Bertagnolli, JA Fletcher. <u>Journal of Clinical Oncology</u> 26(33):5360-5357, 2008 PMID: 18955451	GI	12/15/00	9/1/01
S0336 (2520)	Phase II trial of romidepsin (NSC-630176) in Previously treated colorectal cancer patients with Advanced disease: a Southwest Oncology Group study. RP Whitehead, C Rankin, PMG Hoff, PJ Gold, KG Billingsley, RA Chapman, L Wong, JH Ward, JL Abbruzzese, CD Blanke. <u>Investigational New Drugs</u> , 2008 Oct 2. [Epub ahead of print] PMID:18941712	GI	4/15/04	9/1/05
R9811	Fluorouracil, mitomycin, and radiotherapy vs fluorouracil cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JA Ajani, KA Winter, LL Gunderson, J Pedersen, AB Benson, CR Thomas, RJ Mayer, MG Haddock, TA Rich, C Willett. <u>Journal of the American Medical Association</u> 299(16):1914-21, 2008. PMID: 18430910	GI	1/15/04	2/12/08
N9741 (2704)	Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. HK Sanoff, DJ Sargent, ME Campbell, RF Morton, CS Fuchs, RK Ramanathan, SK Williamson, BP Findlay, HC Pitot, RM Goldberg. <u>Journal of Clinical Oncology</u> 26(35):5721-5727, 2008. PMID: 19001325	GI	4/1/00	7/18/02

C89803 (2491)	Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JA Chan, JA Meyerhardt, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, J Thomas, PL Schaefer, R Whittom, A Hantel, RM Goldberg, RS Warren, M Bertagnolli, C. Fuchs. <u>Journal of the American Medical Association</u> , 299(21):2515-2523, 2008. PMID: 18523220	GI/CC	7/15/00	5/15/01
C89803 (2588)	Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and leukemia Group B 89803. JA Meyerhardt, D Niedzwiecki, Hollis, LB Saltz, RJ Mayer, H Nelson, R Whittom, A Hantel, J Thomas, CS Fuchs. <u>Journal of Clinical Oncology</u> 26(25):4109-4115, 2008. PMID: 18757324	GI/CC	7/15/00	5/15/01

MANUSCRIPTS SUBMITTED/ACCEPTED

9511 (2170)	A Southwest Oncology Group phase II study of trimetrexate, 5FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. CD Blanke, K Chansky, KL Christman, SA Hundahl, BF Issell, PJ Van Veldhuizen Jr, GT Budd, JL Abbruzzese, JS Macdonald. Accepted by <u>American Journal of Clinical Oncology</u> , 12/3/08.	GI	1/15/97	11/15/98
----------------	--	----	---------	----------

ABSTRACTS PUBLISHED/PRESENTED

*9304 (I-0144) 2478	Pelvic failure (PF) analysis in INTO144: evaluation of chemotherapy regimen, risk group stratification, and nodal count. SR Smalley, C Rankin, J Benedetti, SK Williamson, JM Robertson, R Tyvin, JA Martenson, AB Benson, RJ Mayer, C Cripps. Proceedings of 2008 American Society for Therapeutic Radiation Oncology, <u>International Journal of Radiation Oncology Biology Physics</u> 72:S70, 2008	GI	3/1/91	10/1/98
S9304 (2412)	Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among stage II or III rectal cancer patients (SWOG 9304). RS Holmes, C Rankin, KW Makar, JK Benedetti, SR Smalley, CD Blanke, HJ Lenz, CM Ulrich. <u>Proceedings of the American Association for Cancer Research</u> , abstract #4797, 2008.	GI	3/1/91	10/1/98
S9304 (2526)	Polymorphisms in folate-metabolizing enzymes and response to 5-Fluorouracil among stage II or III rectal cancer patients (SWOG 9304). CM Ulrich, C Rankin, RS Holmes, KW Makar, JK Benedetti, SR Smalley, CD Blanke, HJ Lenz.. <u>American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium</u> , abstract #309.	GI	3/1/94	8/1/00
S9304 (2525)	Pharmacogenetic analysis of stage II/III rectal cancer patients treated with 5-Fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). W. Zhang, CJ Rankin, F Nagashima, CM Ulrich, RS Holmes, KW Makar, JK Benedetti, CD Blanke, SR Smalley, JH Lenz. <u>American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium</u> , abstract #300.	GI	3/1/94	8/1/00

S9304 (2510)	An update of pharmacogenetic analysis of adjuvant rectal cancer patients treated with 5-Fluorouracil and pelvic radiation in a phase III intergroup trial (INT-0144, SWOG 9304). W. Zhang, CJ Rankin, KD Danenberg, JK Benedetti, PV Danenberg, CM Ulrich, RS Holmes, KW Makar, CD Blanke, SR Smalley, HJ Lenz. <u>Journal of Clinical Oncology</u> , 26(15S):206s, #4115, 2008	GI	3194	8/1/00
*S0415 (2517)	Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group study. PJ Gold, B Goldman, S Iqbal, LP Leichman, H J Lenz, C D Blanke. <u>Journal of Clinical Oncology</u> , 26(15S):222s, #4536, 2008.	GI	10/15/04	1/1/07
S0415 (2527)	Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group study. PJ Gold, B Goldman, S Iqbal, LP Leichman, H J Lenz, C D Blanke. <u>American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium</u> , abstract #96.	GI	10/15/04	1/1/07

*presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2007**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9008 (2451)	Improved regional control and survival with "low maruyama index" surgery in gastric cancer: autopsy findings from the Dutch D1-D2 trial. SA Hundahl, KCJM Peeters, EK Kranenbarg, H Hartgrink, CJH van de Velde. <u>Gastric Cancer</u> 10(2):84-86, 2007.	GI	8/1/91	7/15/98
9008 (2452)	Gastric cancer: D2 dissection or low maruyama index-based surgery – a debate. HO Douglass, SA Hundahl, JS Macdonald, VP Khatri. <u>Surgical Oncology Clinics of North America</u> 16(1):133-155, 2007.	GI	8/1/91	7/15/98
9700 (2259)	Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. WH Isacoff, JK Benedetti, PA Philip, JL Barstis, AR Jazieh, JS Macdonald. <u>Journal of Clinical Oncology</u> 25(13):1665-1669, 2007. PMID 17470859	GI	9/15/97	6/1/01
C80405 (2594)	Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. <u>Clinical Colorectal Cancer</u> 6(7):536-538, 2007. PMID: 17553204	GI	10/1/05	
C89803	Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. H Nelson, R Whittom, A Hantel, J Thomas, CS Fuchs. <u>Journal of the American Medical Association</u> 298(7):754-764, 2007. PMID: 17699009	GI	7/15/00	5/15/01
C89803 (2464)	Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. LB Saltz, D Niedzwiecki, D Hollis, RM Goldberg, A Hantel, JP Thomas, AL Fields, RJ Mayer. <u>Journal of Clinical Oncology</u> 25(23):3456-3461, 2007. PMID: 17687149	GI	7/15/00	5/15/01
ABSTRACTS PUBLISHED/PRESENTED				
S0205 (2345)	Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (Pca): SWOG S0205 study. PA Philip, J Benedetti, C Fenoglio-Preiser, M Zalupski, H Lenz, E O'Reilly, R Wong, J Atkins, J Abruzzese, C Blanke. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S): #LBA4509, 2007.	GI	1/1/04	4/1/06

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
S0413 (2352)	S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. S Iqbal, B Goldman, HJ Lenz, CM Fenoglio-Preiser, CD Blanke. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#4621, 2007.	GI	12/15/04	5/15/06
S0413 (2399)	Gene expression levels of HER2 and IL-8 and polymorphism in IL-8 associated with clinical outcome in advanced or metastatic gastric cancer treated with lapatinib in SWOG 0413 trial. H Chang, M Azuma, B Goldman, F Nagashima, S Iqbal, K Danenberg, J Benedetti, W Zhang, C Blanke, H Lenz. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#4647, 2007.	GI	12/15/04	5/15/06
S0514 (2354)	SWOG 0514: a phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangiocarcinomas. AB El-Khoueiry, C Rankin, HJ Lenz, P Philip, SE Rivkin, CD Blanke. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#4639, 2007.	GI	10/01/05	01/01/07
R9704 (2398)	Correlation of RTOG 9704 (adjuvant therapy (rx) of pancreatic adenocarcinoma (pan ca)) radiation therapy quality assurance scores (RTQASc) with survival (S). RA Abrams, KA Winter, WF Regine, H Safran, JP Hoffman, AA Konski, AB Benson, JS Macdonald, TA Rich, CG Willett. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 25(18S):#4523, 2007.	GI	5/1/99	7/26/02

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2006**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9008 (2451)	Low maruyama index surgery for gastric cancer. SA Hundahl. <u>Scandinavian Journal of Surgery</u> 95(4):243-248, 2006.	GI	8/1/91	7/15/98
9304 (2300)	Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. SR Smalley, JK Benedetti, SK Williamson, JM Robertson, NC Estes, T Maher, B Fisher, TA Rich, JA Martenson, JW Kugler, AB Benson III, DG Haller, RJ Mayer, JN Atkins, C Cripps, J Pederson, PO Periman, MS Tanaka Jr, CG Leichman, JS Macdonald. <u>Journal of Clinical Oncology</u> 24(22):3542- 3547, 2006.	GI	3/1/94	8/1/00
S9915 (2164)	Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. JH Doroshow, S McCoy, JS Macdonald, BF Issell, T Patel, PW Cobb, KJ Yost, JL Abbruzzese. <u>Investigational New Drugs</u> 24:537-542, 2006.	GI	2/15/01	9/1/02
S9923 (2172)	Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: a Southwest Oncology Group study. RP Whitehead, S McCoy, JS Macdonald, SE Rivkin, MA Neubauer, SR Dakhil, HJ Lenz, MS Tanaka, JL Abbruzzese. <u>Investigational New Drugs</u> 24:335-341, 2006.	GI	6/1/00	8/1/01
S0101 (2186)	Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer. a Southwest Oncology Group (SWOG) trial. SK Williamson, SA McCoy, DR Gandara, SR Dakhil, KJ Yost, JC Paradelo, JN Atkins, CD Blanke, JL Abbruzzese. <u>American Journal of Clinical Oncology</u> 29(2):116-122, 2006.	GI	4/15/01	2/1/03
S0107 (2171)	A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. RP Whitehead, S McCoy, SE Rivkin, HM Gross, ME Conrad, GC Doolittle, RA Wolff, JW Goodwin, SR Dakhil, JL Abbruzzese. <u>Investigational New Drugs</u> 24:515-520, 2006.	GI	7/1/01	6/1/03
S0127 (2269)	Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. T Dragovich, S McCoy, CM Fenoglio-Preiser, J Wang, JK Benedetti, AF Baker, CB Hackett, SG Urba, KS Zaner, CD Blanke, JL Abbruzzese. <u>Journal of Clinical Oncology</u> 24(30):4922-4927, 2006.	GI	6/1/02	8/15/03

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
C89803 (2334)	Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. JA Meyerhardt, D Heseltine, D Niedzwiecki, D Hollis, LB Saltz, RJ Mayer, J Thomas, H Nelson, R Whittom, A Hantel, RL Schilsky, CS Fuchs. <u>Journal of Clinical Oncology</u> 24(22): 3535-3541, 2006.	GI	7/15/00	5/15/01
ABSTRACTS PUBLISHED/PRESENTED				
S0202 (2239)	SWOG S0202 a phase II trial of gemcitabine and capecitabine in patients (pts) with unresectable or metastatic gall bladder cancer or cholangiocarcinoma. S Iqbal, S McCoy, HJ Lenz, SE Rivkin, JN Atkins, CD Blanke. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S): #4134, 2006.	GI	9/1/03	4/1/05
S0336 (2245)	Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. RP Whitehead, S McCoy, IS Wollner, L Wong, WG Harker, CD Blanke. American Society of Clinical Oncology <u>2006 Gastrointestinal Cancers Symposium</u> #255, 2006.	GI	4/15/04	9/1/05
S0336 (2246)	Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: a Southwest Oncology Group study. RP Whitehead, S McCoy, IS Wollner, L Wong, WG Harker, PM Hoff, PJ Gold, KG Billingsley, CD Blanke. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#3598, 2006.	GI	4/15/04	9/1/05
R9704 (2247)	Markers of folate metabolism in pancreatic cancer: thymidylate synthase, thymidine phosphorylase, and MTHFR. results from the RTOG 9704 prospective randomized adjuvant treatment trial. JJ Farrell, K Winter, M Van Rijnsoever, W Regine, R Abrams, H Safran, J Macdonald, A Bowen Benson, C Willett, H Elsaleh. American Society of Clinical Oncology <u>2006 Gastrointestinal Cancers Symposium</u> #144, 2006.	GI	5/1/99	7/26/02
R9704 (2244)	RTOG 9704 a phase III study of adjuvant pre and post chemo-radiation (CRT) 5-fu vs. gemcitabine (G) for resected pancreatic adenocarcinoma. WF Regine, KW Winter, R Abrams, H Safran, JP Hoffman, A Konski, AB Benson, JS Macdonald, CG Willett, TA Rich. Proc of the American Society of Clinical Oncology, <u>Journal of Clinical Oncology</u> 24(18S):#4007, 2006.	GI	5/1/99	7/26/02

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2005**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8899 (2280)	Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. DG Haller, PJ Catalano, JS Macdonald, MA O'Rourke, MS Frontiera, DV Jackson, RJ Mayer. <u>Journal of Clinical Oncology</u> 23(34):8671-8678, 2005.	GI	9/15/88	7/30/92
9008 (2447)	Evidence-based recommendations for local-regional control of gastric cancer. SA Hundahl. <u>Cancer Investigation</u> 23(4):352-362, 2005.	GI	8/1/91	7/15/98
9008 (2448)	Chapter 45 – Stomach. SA Hundahl, JS Macdonald, SR Smalley. In: Chang AE, Ganz PA, Hayes DF, et al. (eds). <u>Oncology: An Evidence Based Approach</u> , New York: Springer-Verlag, pgs 680-703, Dec. 2005.	GI	8/1/91	7/15/98
9008 (2449)	Changing gastric cancer treatment in the United States and the pursuit of quality. SA Hundahl, HJ Wanebo. <u>European Journal of Surgical Oncology</u> 31(6):605-615, 2005.	GI	8/1/91	7/15/98
9008 (2450)	Low maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. KCMJ Peeters, SA Hundahl, EK Kranenbarg, H Hartgrink, CJH van de Velde. <u>World Journal of Surgery</u> 29:1576-1584, 2005.	GI	8/1/91	7/15/98
9415 (2163)	Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. EA Poplin, JK Benedetti, NC Estes, DG Haller, RJ Mayer, RM Goldberg, GR Weiss, SE Rivkin, JS Macdonald. <u>Journal of Clinical Oncology</u> 23(9): 1819-1825, 2005.	GI	12/1/94	12/15/99
9420 (2187)	Assessment of infusional 5-fluorouracil schedule and dose intensity. a Southwest Oncology Group and Eastern Cooperative Oncology Group study. CG Leichman, JK Benedetti, MM Zalupski, H Hochster, AF Shields, HJ Lenz, JL Wade III, JD Bearden III, JS Macdonald. <u>Clinical Colorectal Cancer</u> 5(2):119-123, 2005.	GI	4/15/95	5/15/99
S9924 (2092)	A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. a Southwest Oncology Group (SWOG 99241) study. JS Macdonald, S McCoy, RP Whitehead, S Iqbal, JL Wade III, JK Giguere, JL Abbruzzese. <u>Investigational New Drugs</u> 23:485-487, 2005.	GI	6/1/00	6/1/01
Multiple Studies	Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.	GI		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

(2165)	K Chansky, J Benedetti, JS Macdonald. <u>Cancer</u> 103(6): 1165-1171, 2005.			
--------	--	--	--	--

ABSTRACTS PUBLISHED/PRESENTED

S0127 (2106)	SWOG 0127: Phase II trial of erlotinib in GEJ and gastric adenocarcinomas. T Dragovich, S McCoy, SG Urba, KS Zaner, CM Fenoglio-Preiser, CD Blanke, JL Abbruzzese. <u>American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium</u> #49, 2005.	GI	6/1/02	8/15/03
-----------------	--	----	--------	---------

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2004**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9100 (1364)	A phase II study of high-dose 24-hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group study. RP Whitehead, JK Benedetti, JL Abbruzzese, B Ardlan, JW Goodwin, SP Balcerzak, WE Samlowski, HJ Lenz, JS Macdonald. <u>Investigational New Drugs</u> 22:335-341, 2004.	GI	1/15/93	8/1/94
9107 (2006)	A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer. A Southwest Oncology Group study. RP Whitehead, JK Benedetti, JL Abbruzzese, B Ardlan, S Williamson, ER Gaynor, SP Balcerzak, JS Macdonald. <u>Investigational New Drugs</u> 22:467-473, 2004.	GI	1/1/93	8/1/94
9303 (2115)	Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of Intergroup protocol 0130. JA Martenson Jr, CG Willett, DJ Sargent, JA Mailliard, JH Donohue, LL Gunderson, CR Thomas Jr, B Fisher, AB Benson, R Myerson, RM Goldberg. <u>Journal of Clinical Oncology</u> 22(16):1-7, 2004.	GI	8/15/93	12/17/96
S9801 (1850)	Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group study. SG Urba, K Chansky, PJ vanVeldhuizen, RE Pluenneke, JK Benedetti, JS Macdonald, JL Abbruzzese. <u>Investigational New Drugs</u> 22:91-97, 2004.	GI	4/1/98	6/15/99
ABSTRACTS PUBLISHED/PRESENTED				
9008 (2108)	Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: update of the results of Intergroup study INT-0116 (SWOG 9008). JS Macdonald, S Smalley, J Benedetti, N Estes, DG Haller, JA Ajani, LL Gunderson, M Jessup, JA Martenson. <u>American Society Of Clinical Oncology Gastrointestinal Cancers Symposium</u> #6, 2004.	GI	8/1/91	7/15/98
S0101 (2041)	SWOG 0101: Evaluation of gemcitabine and irinotecan in esophageal cancer: SK Williamson, S McCoy, JL Abbruzzese. <u>American Society of Clinical Oncology Gastrointestinal Cancers Symposium</u> #25, 2004.	GI	4/15/01	2/1/03
*S0107 (2060)	A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group study. RP Whitehead, SA McCoy, SE Rivkin, HM Gross, ME Conrad, JL Abbruzzese. <u>Proc of the American Society of Clinical Oncology</u> 23:315	GI	6/1/03	6/1/03

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	(#4012), 2004.			
N9741 (2100)	Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): results from Intergroup Trial N9741. C Fuchs, M Pollak, DJ Sargent, JA Meyerhardt, RK Ramanathan, S Williamson, B Findlay, E Green, RM Goldberg. <u>Proc of the American Society of Clinical Oncology</u> 23:250 (#3521), 2004.	GI	4/1/00	7/18/02
*N9741 (2101)	N9741: FOLFOX (oxaliplatin(oxal)/ 5-fluorouracil (5-FU)/ leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study. RM Goldberg, DJ Sargent, RF Morton, C Fuchs, RK Ramanathan, SK Williamson, BP Findlay, HR Pitot, SR Alberts. <u>Proc of the American Society of Clinical Oncology</u> 23:275 (#3621), 2004.	GI	4/1/00	7/18/02
*N9741 (2144)	N9741: Oxaliplatin (Oxal) + CPT-11 or 5-fluorouracil (5FU)/ leucovorin (LV) in advanced colorectal cancer (CRC): final Efficacy data from an intergroup study. RM Goldberg, RF Morton, DJ Sargent, CS Fuchs, RK Ramanathan, SK Williamson, BP Findley. <u>American Society of Clinical Oncology Gastrointestinal Cancers Symposium</u> #215, 2004.	GI	4/1/00	7/18/02
*N9741 (2123)	Preliminary evidence of relationship between genetic markers and oncology patient quality of life (QOL). JA Sloan, H McLeod, D Sargent, X Zhao, C Goldberg. <u>Proc of the American Society of Clinical Oncology</u> 23:2 (#5), 2004.	GI	4/1/00	7/18/02

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2003**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9041 (1821)	Adenoma recurrences after resection of colorectal carcinoma: GI Results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study. DZJ Chu, K Chansky, DS Alberts, FL Meyskens Jr, CM Fenoglio-Preiser, SE Rivkin, GM Mills, JK Giguere, GE Goodman, JL Abbruzzese, SM Lippman. <u>Annals of Surgical Oncology</u> 10(8):870-875, 2003.	GI	2/1/93	4/15/99
9045 (1989)	Pattern mixture models for longitudinal quality of life studies in GI advanced stage disease. DK Pauler, S McCoy, C Moynour. <u>Statistics in Medicine</u> 22:795-809, 2003.	GI	3/1/91	1/15/93
ABSTRACTS PUBLISHED/PRESENTED				
9008 (2065)	Frequent alterations of B-catenin gene in gastric cancers with GI microsatellite instability. J Wang, T Shepherd, A Lowy, A Noffsinger, G Stemmermann, C Fenoglio-Preiser. <u>Proc of the American Association for Cancer Research</u> 44 (2 nd ed): #1199, 2003.	GI	8/1/91	7/15/98
*9304 (1877)	Intergroup 0144 – phase III trial of 5-FU based chemotherapy GI regimens plus radiotherapy (XRT) in postoperative adjuvant rectal cancer. Bolus 5-FU vs prolonged venous infusion (PVI) before and after XRT + PVI vs bolus 5-FU + leucovorin (LV) + levamisole (LEV) before and after XRT + bolus 5-FU + LV. SR Smalley, J Benedetti, S Williamson, J Robertson, B Fisher, J Martenson Jr, AB Benson, M Robert, C Cripps, J Macdonald. <u>Proc of the American Society of Clinical Oncology</u> 22:251 (#1006), 2003.	GI	3/1/94	8/1/00
S9923 (1882)	Phase II trial of R115777 (NSC# 70818) in patients with GI advanced colorectal cancer: a Southwest Oncology Group study. RP Whitehead, S McCoy, J Macdonald, SE Rivkin, M Neubauer, S Dakhil, H-J Lenz, M Tanaka, JL Abbruzzese. <u>Proc of the American Society of Clinical Oncology</u> 22:272 (#1092), 2003.	GI	6/1/00	8/1/01

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2002**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8899 (1924)	Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. AD McCollum PJ Catalano, DG Haller, RJ Mayer, JS Macdonald, AB Benson III, CS Fuchs. <u>Journal of the National Cancer Institute</u> 94(15):1160-1167, 2002.	GI	9/15/88	7/30/92
8899 (1841)	Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. RJ Green, JP Metlay, K Propert, PJ Catalano, JS Macdonald, RJ Mayer, DG Haller. <u>Annals of Internal Medicine</u> 136(4):261-269, 2002.	GI	9/15/88	7/30/92
8990 (1751)	Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an Intergroup study. MM Kemeny, S Adak, B Gray, JS Macdonald, T Smith, S Lipsitz, ER Sigurdson, PJ O'Dwyer, AB Benson III. <u>Journal of Clinical Oncology</u> 20(6):1499-1505, 2002.	GI	8/15/90	1/31/97
9006 (1622)	Does leucovorin alter the intratumoral pharmacokinetics of 5-fluorouracil (5-FU)? a Southwest Oncology Group study. CA Presant, J Jacobson, W Wolf, V Waluch, IC Weitz, JS Macdonald. <u>Investigational New Drugs</u> 20:369-376, 2002.	GI	10/15/90	11/1/96
9008 (1836)	B-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer. WM Clements, J Wang, A Sarnaik, OJ Kim, JS Macdonald, C Fenoglio-Preiser, J Groden, AM Lowy. <u>Cancer Research</u> 62:3503-3506, 2002.	GI	8/1/91	7/15/98
9008 (1923)	Surgical Quality in Trials of Adjuvant Cancer Therapy. SA Hundahl. <u>Journal of Surgical Oncology</u> 80:177-180, 2002.	GI	8/1/91	7/15/98
9008 (1905)	Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. SA Hundahl, JS Macdonald, J Benedetti, T Fitzsimmons. <u>Annals of Surgical Oncology</u> 9(3):278-286, 2002.	GI	8/1/91	7/15/98
9040 (1919)	Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. JE Tepper, M O'Connell, D Niedzwiecki, DR Hollis, AB Benson III, B Cummings, LL Gunderson, JS Macdonald, JA Martenson, RJ Mayer. <u>Journal of Clinical Oncology</u> 20(7):1744-1750, 2002.	GI	9/15/90	11/22/92
9040	Impact of TNM stage on survival and disease control in	GI	9/15/90	11/22/92

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1987)	adjuvant rectal cancer pooled analysis. LL Gunderson, DJ Sargent, J Tepper, MJ O'Connell, C Allmer, SR Smalley, JA Martenson, DG Haller, R Mayer, TA Rich. <u>Int J Radiol Oncol Biol Phys</u> 51(3):8-9 (#10), 2001.			
9411 (1991)	Short-term quality-of-life outcomes following laparoscopic assisted colectomy vs open colectomy for colon cancer. JC Weeks, H Nelson, S Gelber, D Sargent, G Schroeder. <u>Journal of the American Medical Association</u> 287(3):321-328, 2002.	GI	10/1/94	8/31/01
S9629 (1823)	Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ML Rothenberg, JK Benedetti, JS Macdonald, TE Seay, MA Neubauer, CS George, MS Tanaka Jr, JK Giguere, BT Pruitt, JL Abbruzzese. <u>Annals of Oncology</u> 13:1576-1582, 2002.	GI	5/15/97	3/15/99
S9635 (1807)	Biochemical modulation of 5-fluorouracil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. CG Leichman, K Chansky, JS Macdonald, MA Doukas, GT Budd, JK Giguere, JL Abbruzzese. <u>Investigational New Drugs</u> 20:419-424, 2002.	GI	4/1/98	8/31/00
E1295 (2424)	Randomized trial of standard dose loperamide, low-dose octreotide acetate, or high dose octreotide acetate for chemotherapy induced diarrhea (E1295): an Intergroup study of the Eastern Cooperative Oncology Group. S Wadler, L Ryan, ML Rothenberg, C Cleeland, D Cella, JK Giguere, L Stucky-Marshall, AB Benson. In: Lambers SWJ and Dogliotti L, eds. <u>Advances in Oncology: the expanding role of octreotide I</u> . Bioscientifica Press, Bristol, UK, pp 227-234, 2002.	GI	1/15/97	2/15/99
ABSTRACTS PUBLISHED/PRESENTED				
9008 (1862)	B-catenin nuclear staining and mutation in gastric cancer. OJ Kim, J Wang, WM Clements, AA Sarnaik, G Stemmermann, A Noffsinger, G DeVoe, AM Lowey, C Fenoglio-Preiser. <u>Modern Pathology</u> 15(1):132a (#551), 2002.	GI	8/1/91	7/15/98
9008 (1897)	Beta-catenin is commonly mutated in human gastric cancers with cyclin D overexpression. J Wang, ONJ Kim, WM Clements, AA Sarnaik, B Liu, A Noffsinger, G Stemmermann, AM Lowy, CM Fenoglio-Preiser. <u>Proc of the American Association for Cancer Research</u> 93:90 (#526), 2002.	GI	8/1/91	7/15/98
9008 (1898)	Mutation of the B-catenin gene is a frequent cause of Wnt pathway activation in gastric cancer. WM Clements, J Wang, A Sarnaik, OJ Kim, JL Groden, C Fenoglio-Preiser, AM Lowy. <u>Proc of the American Association for Cancer Research</u> 93:111 (#770), 2002.	GI	8/1/91	7/15/98
9041	Adenoma recurrences after resection of colorectal carcinoma	GI	2/1/93	4/15/99

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1820)	(CRC). Results from the SWOG 9041 calcium chemoprevention pilot study. D Chu, K Chansky, C Fonoglio-Preiser, D Alberts, R Meyskens, G Goodman, S Lippman. <u>Annals of Surgical Oncology</u> 9(1) Suppl:S24 (#52), 2002.			
S9700 (1792)	Continuous infusion (CI) 5 fluorouracil (5FU), leucovorin (LV), mitomycin C (Mito C) and dipyridamole (D) in patients with locally advanced unresectable pancreatic adenocarcinoma- a phase II trial of the Southwest Oncology Group. WH Isacoff, J Benedetti, JS Macdonald, JL Abbruzzese. <u>Proc of the American Society of Clinical Oncology</u> 21:137a (#544), 2002.	GI	9/15/97	6/1/01
S9924 (1798)	A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. a Southwest Oncology Group (SWOG) study. JS Macdonald, K Chansky, R Whitehead, J Wade, J Giguere, JL Abbruzzese. <u>Proc of the American Society of Clinical Oncology</u> 21:138a (#548), 2002.	GI	6/1/00	6/1/01
N9741 (1837)	N9741: oxaliplatin (oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Initial toxicity and response data from a GI Intergroup study. RM Goldberg, RF Morton, DJ Sargent, CS Fuchs, RK Ramanathan, SK Williamson, BP Findlay. <u>Proc of the American Society of Clinical Oncology</u> 21:128a (#511), 2002.	GI	4/1/00	

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2001**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9008 (1734)	Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. JS Macdonald, SR Smalley, J Benedetti, SA Hundahl, NC Estes, GN Stemmermann, DG Haller, JA Ajani, LL Gunderson, JM Jessup, JA Martenson. <u>New England Journal of Medicine</u> 345(10):725-730, 2001.	GI	8/1/91	7/15/98
9008 (1914)	Gastric Cancer. JS Macdonald. <u>Clinical Oncology Updates</u> 4(3):1-7, 2001.	GI	8/1/91	7/15/98
9040 (1918)	Impact of number of nodes retrieved on outcome in patients with rectal cancer. JE Tepper, MJ O'Connell, D Niedzwiecki, D Hollis C Compton, AB Benson III, B Cummings, L Gunderson, JS Macdonald, RJ Mayer. <u>Journal of Clinical Oncology</u> 19(1):157-163, 2001.	GI	9/15/90	11/22/92
Multiple Studies (1851)	A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. DJ Sargent, RM Goldberg, SD Jacobson, JS Macdonald, R Labianca, DG Haller, LE Shepherd, JF Seitz, G Francini. <u>New England Journal of Medicine</u> 345(15):1091-1097, 2001.	GI		
ABSTRACTS PUBLISHED/PRESENTED				
*8899 (1757)	Outcomes and toxicity in African-American and Caucasian patients receiving adjuvant chemotherapy for colon cancer: a secondary analysis of INT-0089. AD McCollum, PJ Catalano, DG Haller, RJ Mayer, JS Macdonald, AB Benson III, CS Fuchs. <u>Proc of the American Society of Clinical Oncology</u> 20:133a (#528), 2001.	GI	9/15/88	7/30/92
9008 (1736)	E-cadherin, a and b-catenins in gastric cancer expression. OJ Kim, G Stemmermann, G DeVoe, A Noffsinger, J Macdonald, C Fenoglio-Preiser. <u>Modern Pathology</u> 14:88A (#506), 2001	GI	8/1/91	7/15/98
9040 (1987)	Impact of TNM stage on survival and disease control in adjuvant rectal cancer pooled analysis. LL Gunderson, DJ Sargent, J Tepper, MJ O'Connell, C Allmer, SR Smalley, JA Martenson, DG Haller, R Mayer, TA Rich. <u>Int J Radiol Oncol Biol Phys</u> 51(3):8-9 (#10), 2001.	GI	9/15/90	11/22/92
*9401 (1732)	Phase III trial of 5-fluorouracil (5FU), levamisole (LEV), +/- leucovorin (LV) as adjuvant treatment (ADJ) of resected metastatic colorectal cancer (M-CRC) an NCCTG/M.D. Anderson/SWOG study. RM Goldberg, R Langdon, DJ Sargent, R Pazdur, A Hantel, HS Wieand, M O'Connell,	GI	8/15/94	9/10/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	C Kardinal, K Rowland, J Kugler. <u>Proc of the American Society of Clinical Oncology</u> 20:133a (#527), 2001.			
*9420 (1719)	Phase III trial of protracted infusion (PI) vs intermittent high-dose infusion (HDI) 5-fluorouracil (5-FU) in patients (PTS) with disseminated colorectal cancer (DCRC). a Southwest Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG) study. CG Leichman, J Benedetti, H Hochster, M Zalupski, A Benson, J Macdonald. <u>Proc of the American Society of Clinical Oncology</u> 20:125a (#497), 2001.	GI	4/15/95	5/15/99
S9801 (1721)	Gemcitabine and cisplatin chemotherapy for patients with metastatic or recurrent esophageal carcinoma. K Chansky, S Urba, S Taylor, J Paradelo, J Abbruzzese. <u>Proc of the American Society of Clinical Oncology</u> 20:161a (#641), 2001.	GI	4/1/98	6/15/99
*Presented				

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
2000**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9008 (1556)	Alterations in exon 4 of the <i>p53</i> gene in gastric carcinoma. T Shepherd, D Tolbert, J Benedetti, J Macdonald, G Stemmermann, J Wiest, G DeVoe, MA Miller, J Wang, A Noffsinger, C Fenoglio-Preiser. <u>Gastroenterology</u> 118:1039-1044, 2000.	GI	8/1/91	7/15/98
9045 (1200)	Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. CM Moinpour, JS Triplett, B McKnight, L Lovato, C Upchurch, CG Leichman, FM Muggia, L Tanaka, WA James, M Lennard, FL Meyskens Jr. <u>Psycho-Oncology</u> 9:340-354, 2000.	CCR GI	3/1/91	1/15/93
9339 (1551)	A phase II trial of topotecan in esophageal carcinoma: A Southwest Oncology Group study (SWOG 9339). JS Macdonald, JL Jacobson, SJ Ketchel, G Weiss, S Taylor, G Mills, JP Kuebler, S Rivkin, M Conrad. <u>Investigational New Drugs</u> 18:199-202, 2000.	GI	3/1/94	12/15/95
9413 (1552)	A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: A Southwest Oncology Group study (SWOG-9413). JS Macdonald, JL Jacobson, M Modiano, DF Moore Jr, DR Gandara, LE Schroder, RA Chapman. <u>Investigational New Drugs</u> 18:269-273, 2000.	GI	5/1/95	3/15/96
ABSTRACTS PUBLISHED/PRESENTED				
8591 (1681)	Clinical correlation for colorectal cancers with microsatellite instability (MSI). DP Chauhan, LC Lovato, A Goel, T Aoki, CR Boland, DJ Ahnen. <u>Gastroenterology</u> 118(4) Suppl:A58 (#499), 2000.	GI	1/14/85	10/1/87
*8899 (1665)	Colon cancer survival is associated with increasing number of lymph nodes removed. A secondary analysis of INT-0089. TE Lo Voyer, ER Sigurdson, AL Hanlon, RJ Mayer, JS Macdonald, PJ Catalano, DG Haller. <u>Proc of the American Society of Clinical Oncology</u> 19:239a (#925), 2000.	GI	9/15/88	7/30/92
9006 (1601)	Effects of leucovorin (LV) on the intratumoral (IT) pharmacokinetics (PK) of 5-fluorouracil (5-FU) – a Southwest Oncology Group (SWOG) study. W Wolf, CA Present, V Waluch, I Weitz, J Jacobson. <u>Proc of the American Association for Cancer Research</u> 41:611 (#3885), 2000.	GI	10/15/90	11/1/96
*9006 (1602)	Spectroscopic evaluation of intratumoral (IT) metabolic modulation (MM) of 5-fluorouracil (5-FU) by leucovorin (LV):	GI	10/15/90	11/1/96

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
	correlation of human tumor pharmacokinetics (PK) with modulation and tumor response. SWOG 9006. CA Presant, W Wolf, V Waluch, I Weitz, J Jacobson. <u>Proc of the American Society of Clinical Oncology</u> 19:194a (#754), 2000.			
9008 (1996)	A simple classification of gastric cancer. OJ Kim, G Stemmermann, A Noffsinger and C Fenoglio-Preiser. <u>Modern Pathology</u> 13(1):83A (#474), 2000.	GI	8/1/91	7/15/98
9008 (1640)	Intergroup 0116 (SWOG 9008) Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal (GE) junction adenocarcinoma (ACA): evaluation of efficacy and radiotherapy treatment planning. S Smalley, J Benedetti, L Gunderson, J Martenson, J Tepper, K Kiel, A Lichter, J Forman, J Macdonald. <u>International Journal of Radiation Oncology-Biology-Physics</u> 48(3) Suppl:111-112 (#3), 2000.	GI	8/1/91	7/15/98
*9008 (1608)	Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup study INT-0116 (SWOG 9008). JS Macdonald, S Smalley, J Benedetti, N Estes, DG Haller, JA Ajani, LL Gunderson, M Jessup, JA Martenson Jr. <u>Proc of the American Society of Clinical Oncology</u> 19:1a (#1), 2000.	GI	8/1/91	7/15/98
*9415 (1610)	Phase III randomized trial of bolus 5-FU/leucovorin/levamisole versus 5-FU continuous infusion/levamisole as adjuvant therapy for high risk colon cancer (SWOG 9415/INT-0153). E Poplin, J Benedetti, N Estes, D Haller, R Mayer, R Goldberg, J Macdonald. <u>Proc of the American Society of Clinical Oncology</u> 19:240a (#931), 2000.	GI	12/1/94	12/15/99

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1999**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9008 (1418)	p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. DM Tolbert, AE Noffsinger, MA Miller, GW Devoe, GN Stemmermann, JS Macdonald, CM Fenoglio-Preiser. <u>Modern Pathology</u> 12(1):54-60, 1999.	GI	8/1/91	7/15/98
9008 (1454)	The relation of p53 gene mutations to gastric cancer subsite and phenotype. D Tolbert, C Fenoglio-Preiser, A Noffsinger, G De Voe, J Macdonald, J Benedetti, GN Stemmermann. <u>Cancer Causes and Control</u> 10:227-231, 1999.	GI	8/1/91	7/15/98
9009 (1411)	Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group protocol 9009. RF Holcombe, J Jacobson, SR Dakhil, RM Stewart, KS Betzing, K Kannan, JS Macdonald. <u>Cancer Immunology and Immunotherapy</u> 48:533-539, 1999.	GI	12/15/90	8/7/92
9051 (1453)	Hepatic chemoembolization combined with systemic infusion of 5-Fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial. CG Leichman, JR Jacobson, JR Daniels, MR Modiano, MM Zalupski, JH Doroshow, WS Fletcher, JS Macdonald. <u>Cancer</u> 86(5):775-781, 1999.	GI	4/15/92	4/1/95
9306 (1749)	Sphincter-sparing treatment for distal rectal adenocarcinoma. GI GD Steele, JE Herndon, R Bleday, A Russell, A Benson, M Hussain, A Burgess, JE Tepper, RJ Mayer. <u>Annals of Surgical Oncology</u> 6(5):433-441, 1999.	GI	7/1/93	10/15/95
ABSTRACTS PUBLISHED/PRESENTED				
8899 (1840)	Surveillance for second primary colon cancers after adjuvant chemotherapy: analysis of INT-0089. RJ Green, JP Metlay, KJ Probert, PJ Catalano, JS Macdonald, RJ Mayer, DG Haller. <u>Proc of the American Society of Clinical Oncology</u> 18:237a (#910), 1999.	GI	9/15/88	7/30/92
*8990 (1534)	Results of the Intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases. MM Kemeny, S Adak, S Lipsitz, B Gray, J Macdonald, AB Benson III. <u>Proc of the American Society of Clinical Oncology</u> 18:264a (#1012), 1999.	GI	8/15/90	1/31/97

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9008 (1529)	Alterations in exon 4 of the p53 gene in gastric cancer. T Shepherd, D Tolbert, A Noffsinger, G Stemmerman, C Fenoglio-Preiser. <u>Proc of the American Association for Cancer Research</u> 40:346 (#2289), 1999.	GI	8/1/91	7/15/98
9008 (1535)	Minisatellite instability in gastric cancer. YE Nikiforov, T Schulte, GN Stemmermann, AN Noffsinger, CM Fenoglio-Preiser. <u>Laboratory Investigation</u> 79:81A (#463), 1999.	GI	8/1/91	7/15/98
*9303 (1518)	A phase III study of adjuvant radiation therapy (RT), 5-Fluorouracil (5-FU), and levamisole (LEV) vs. 5-FU and LEV in selected patients resected, high risk colon cancer: Initial results of INT 0130. J Martenson, C Willett, D Sargent, J Donohue, R Goldberg, T Wasserman, L Gunderson, R Myerson, P Thomas, B Fisher, A Benson. <u>Proc of the American Society of Clinical Oncology</u> 18:235a (#904), 1999.	GI	8/15/93	12/17/96
*9306 (1639)	Failure and salvage after sphincter sparing treatment for distal rectal adenocarcinoma-a CALGB intergroup study. G Steele, J Tepper, J Herndon, R Mayer. <u>Proc of the American Society of Clinical Oncology</u> 18:235a (#903), 1999.	GI	7/1/93	10/15/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1998**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8591 (1479)	Surgery for recurrent colon cancer: Strategies for identifying resectable recurrence and success rates after resection. RM Goldberg, TR Fleming, CM Tangen, CG Moertel, JS Macdonald, DG Haller, JA Laurie. <u>Annals of Internal Medicine</u> 129(1):27-35, 1998.	GI	1/14/85	10/1/87
9000 (1330)	Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. DJ Ahnen, P Feigl, G Quan, C Fenoglio-Preiser, LC Lovato, PA Bunn Jr, G Stemmerman, JD Wells, JS Macdonald, FL Meyskens Jr. <u>Cancer Research</u> 58:1149-1158, 1998.	CCR GI	2/15/91	9/15/93
9008 (1456)	Inadequate documentation and resection for gastric cancer in the United States: A preliminary report. NC Estes, JS Macdonald, K Touijer, J Benedetti, J Jacobson. <u>The American Surgeon</u> 64(7):680-685, 1998.	GI	8/1/91	7/15/98
9013 (1646)	Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. DP Kelsen, R Ginsberg, TF Pajak DG Sheahan, L Gunderson, J Mortimer, N Estes, DG Haller, J Ajani, W Kocha, BD Minsky, JA Roth. <u>New England Journal of Medicine</u> 339(27):1979-1984, 1998.	GI	6/1/90	12/31/95
9045 (1931)	A comparative analysis of quality of life data from a Southwest Oncology Group randomized trial of advanced colorectal cancer. AB Troxel. <u>Statistics In Medicine</u> 17:767-779, 1998	GI	3/1/91	1/15/93
9157 (1387)	Phase II trial of oral β -all trans-retinoic acid in hepatocellular carcinoma (SWOG-9157). FL Meyskens Jr, J Jacobson, B Nguyen, GR Weiss, DR Gandara, JS Macdonald. <u>Investigational New Drugs</u> 16(2):171-173, 1998.	GI	6/1/93	8/1/94

ABSTRACTS PUBLISHED/PRESENTED

*8899 (1414)	Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Five-year final report of INT-0089. DG Haller, PJ Catalano, JS Macdonald, RJ Mayer. <u>Proc of the American Society of Clinical Oncology</u> 17:256a (#982), 1998.	GI	9/15/88	7/30/92
-----------------	---	----	---------	---------

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1997**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
9040 (1305)	Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114. JE Tepper, MJ O'Connell, GR Petroni, D Hollis, E Cooke, AB Benson III, B Cummings, LL Gunderson, JS Macdonald, JA Martenson. <u>Journal of Clinical Oncology</u> 15(5):2030-2039, 1997.	GI	9/15/90	11/22/92
9135 (1226)	Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study. RP Whitehead, J Jacobson, TD Brown, SA Taylor, GR Weiss, JS Macdonald. <u>Journal of Clinical Oncology</u> 15(6):2414-2419, 1997.	GI	6/1/92	1/15/93
9150 (1286)	Phase II trial of topotecan in advanced gastric cancer: A Southwest Oncology Group study. JK Benedetti, HA Burris III, SP Balcerzak, JS Macdonald. Published by <u>Investigational New Drugs</u> 15(3):261-264, 1997.	GI	7/15/92	10/15/93
9151 (1288)	Phase II trial of topotecan in hepatocellular carcinoma: A Southwest Oncology Group study. JG Wall, JK Benedetti, MA O'Rourke, RB Natale, JS Macdonald. <u>Investigational New Drugs</u> 15(3):257-260, 1997.	GI	2/1/92	6/15/93
9241 (1304)	Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241). JS Macdonald, JK Benedetti, M Modiano, DS Alberts. <u>Investigational New Drugs</u> 15:357-359, 1997.	GI	7/15/93	11/15/94
ABSTRACTS PUBLISHED/PRESENTED				
8899 (1839)	Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089. DG Haller, PJ Catalano, JS Macdonald, RJ Mayer. <u>Proc of the American Society of Clinical Oncology</u> 16:265a (#940), 1997.	GI	9/15/88	7/30/92
8899 (1366)	Thymidylate synthase expression as a predictor for response to 5-fluorouracil-based therapy and survival for patients (pts) with resected colon or advanced colorectal cancer. An ECOG study. AB Benson, PJ Catalano, S Rao, DG Haller, PJ O'Dwyer, CJ Allegra, PG Johnston. <u>Proceedings of the American Society of Clinical Oncology</u> 16:258a (#917), 1997.	GI	9/15/88	7/30/92
*9008	Detection of microsatellite instability and p53 gene mutations	GI	8/1/91	7/15/98

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
(1274)	in advanced gastric carcinomas. D Tolbert, A Noffsinger, G Stemmermann, C Fenoglio-Preiser. <u>International Academy of Pathology Book of Abstracts</u> 65A (#369), 1997.			

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
9009 (1233)	Immunologic reconstitution following adjuvant 5FU and levamisole (LMS) correlates with disease free survival in stage III colon cancer: Report of Southwest Oncology Group (SWOG) protocol #9009. RF Holcombe, J Jacobson, JS Macdonald, SR Dakhil, RM Stewart, KS Betzing, K Kannan. <u>Proc American Association for Cancer Research</u> 38:521 (#3494), 1997.	GI	12/15/90	8/7/92
*9013 (1360)	Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: a preliminary report of intergroup study 113 (RTOG 89-11). DP Kelsen, R Ginsberg, C Qian, L Gunderson, J Mortimer, N Estes D Hailer, J Ajani, W Kocha, J Roth, B Minsky. <u>American Society of Clinical Oncology</u> 16:276a (#982), 1997.	GI	6/1/90	12/31/95
*9306 (1363)	Sphincter sparing treatment of distal rectal adenocarcinoma: A phase II intergroup study. GD Steele, JE Herndon, AM Burgess, R Bleday, AH Russell, AB Benson, MA Hussain, RJ Mayer. <u>American Society of Clinical Oncology</u> 16:256a (#908), 1997.	GI	7/1/93	19/15/95

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1996**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8721 (1168)	Phase II trial of trimetrexate in advanced esophageal cancer: A Southwest Oncology Group study. TR Fleming, TD Brown, SW Ross, JS Macdonald. <u>Investigational New Drugs</u> 13:363-365, 1996.	GI	9/1/87	9/1/91
8734 (538)	Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma: A Southwest Oncology Group study. RL Martino, TR Fleming, LM Morrell, B Ardalan, SP Richman, JS Macdonald. <u>Investigational New Drugs</u> 14:419-421, 1996.	GI Dev Ther	3/1/88	1/1/90
9008 (1251)	Immunohistochemical analysis of bcl-2 family proteins in adenocarcinomas of the stomach. M Krajewski, CM Fenoglio-Preiser, S Krajewski, K Song, JS Macdonald, G Stemmerman, JC Reed. <u>American Journal of Pathology</u> 149(5):1449-1457, 1996.	GI	8/1/91	Open
9008 (1273)	Pathologic and phenotypic features of gastric cancer. CM Fenoglio-Preiser, AE Noffsinger, J Belli, GN Stemmermann. <u>Seminars in Oncology</u> 23(3):292-306, 1996.	GI	8/1/91	Open
9060 (1186)	Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060. EA Poplin, J Jacobson, A Herskovic, TJ Panella, M Valdivieso, LF Hutchins, JS Macdonald. <u>Cancer</u> 78(9):1851-1856, 1996.	GI	11/1/91	3/1/93
ABSTRACTS PUBLISHED/PRESENTED				
*8899 (1143)	Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: Preliminary results of INT-0089. DG Haller, PJ Catalano, JS Macdonald, RJ Mayer. <u>American Society of Clinical Oncology</u> 15:211 (#486), 1996.	GI	9/15/88	7/30/92
*9000 (1238)	K-ras mutation and p53 overexpression but not ploidy status predict the clinical behavior of colon cancer. O Gang, D Ahnen, C Fenoglio-Preiser, L Loll, P Bunn, P Feigl. <u>Gastroenterology</u> 110(4):A516, 1996.	GI	2/15/91	9/15/93
*9040 (1193)	Toxicity in the adjuvant therapy of rectal cancer: A preliminary report of Intergroup 0114 (CALGB 9081). J Tepper, M O'Connell, G Petroni, A Benson, J Macdonald, J Martenson, T Rich, H Stern. <u>American Society of Clinical Oncology</u> 15:210 (#481), 1996.	GI	9/15/90	11/22/92

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
*9051 (1145)	Combined hepatic chemoembolization (CE) and systemic continuous infusion 5-FU (CIFU) + leucovorin (LV) for metastatic colorectal cancer (MCC): A phase II Southwest Oncology Group trial. CG Leichman, J Jacobson, M Zalupski, L Leong, J Benedetti. <u>American Society of Clinical Oncology</u> 15:215 (#500), 1996.	GI	4/15/92	4/1/95
9157 (1146)	Phase II trial of β -trans-retinoic acid (TRA) in primary hepatomas (SWOG 9157). FL Meyskens Jr, B Nguyen, J Jacobson, J Macdonald. <u>American Society of Clinical Oncology</u> 15:229 (#559), 1996.	GI	6/1/93	8/1/94
Multiple Studies (1271)	Differential expression of connexin 43 in normal, pre-neoplastic and neoplastic squamous epithelium of the upper aerodigestive tract. W Sakr, P Tabasca, O Kucuk, JS Bertram. <u>American Association for Cancer Research</u> 37:269 (#1834), 1996.	GI		

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1995**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7804 (914)	Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. JS Macdonald, TR Fleming, RF Peterson, JL Berenberg, S McClure, RA Chapman, HJ Eyre, D Solanki, AB Cruz Jr, R Gagliano, NC Estes, CM Tangen, S Rivkin. <u>Annals of Surgical Oncology</u> 2(6):488-494, 1995.	GI	3/10/78	8/15/91
8390 (868)	Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study. JL Berenberg, C Tangen, JS Macdonald, LF Hutchins, RB Natale, N Oishi, JT Guy, TR Fleming. <u>Cancer</u> 76(5):715-719, 1995.	GI	3/16/84	3/1/88
8572 (976)	Adjuvant continuous infusion 5FU, whole abdominal radiation, and tumor bed boost in high-risk stage III colon carcinoma: A Southwest Oncology Group pilot study. C Fabian, S Giri, N Estes, CM Tangen, E Poplin, S Vogel, W Goodwin, S Rivkin, TR Fleming, JS Macdonald. <u>International Journal of Radiation Oncology Biology Physics</u> 32(2):457-464, 1995.	GI	5/9/86	6/15/91
8591 (INT-0035) (1032)	Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. CG Moertel, TR Fleming, JS Macdonald, DG Haller, JA Laurie, CM Tangen, JS Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder, JA Mailliard. <u>Annals of Internal Medicine</u> 122(5):321-326, 1995.	GI	1/14/85	10/1/87
8591 (INT-0035) (1079)	Intergroup Study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. CG Moertel, TR Fleming, JS Macdonald, DG Haller, JA Laurie, CM Tangen, JS Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder, JA Mailliard. <u>Journal of Clinical Oncology</u> 13(12):2936-2943, 1995.	GI	1/14/85	10/1/87
8611 (449)	A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: A Southwest Oncology Group study. TD Brown, TR Fleming, PJ Goodman, JS Macdonald, RP Pugh, T O'Rourke. <u>Anti-Cancer Drugs</u> 6:219-223, 1995.	GI Dev Ther	1/15/87	1/1/88
8905 (1050)	Phase II study of fluorouracil and its modulation in advanced colorectal cancer. A Southwest Oncology Group study. CG Leichman, TR Fleming, FM Muggia, CM Tangen, B Ardalan, JH Doroshow, FJ Meyers, RF Holcombe, GR Weiss, A Mangalik, JS Macdonald. <u>Journal of Clinical Oncology</u> 13(6):1303-1311, 1995.	GI	8/1/89	1/1/93

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8910 (991)	Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. SK Williamson, CM Tangen, A Maddox, CH Spiridonidis, JS Macdonald. <u>American Journal of Clinical Oncology (CCT)</u> 18(6):484-487, 1995.	GI	1/15/90	8/1/92
ABSTRACTS PUBLISHED/PRESENTED				
*9060 (1083)	Evaluation of multimodality treatment of locoregional esophageal carcinoma: SWOG 9060. E Poplin, A Herskovic, J Jacobson, T Panella, J Macdonald. <u>ASCO</u> 14:202 (#486), 1995.	GI	11/1/91	3/1/93

*Presented

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1994**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8411 (901)	Phase II trial of dimethyl triazeno imidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. RM Bukowski, CM Tangen RF Peterson, SA Taylor, JJ Rinehart, HJ Eyre, SE Rivkin, T Fleming, JS Macdonald. <u>Cancer</u> 73(5):1505-1508, 1994.	GI	07/24/84	02/15/88
8623 (997)	Phase II trial of trimetrexate in untreated advanced gastric carcinoma. A Southwest Oncology Group study. A Hantel, CM Tangen, JS Macdonald, SP Richman, RP Pugh, T Pollock. <u>Investigational New Drugs</u> 12:155-157, 1994.	GI	8/15/87	1/1/89
8896 (INT-0114) (1028)	Improved adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. MJ O'Connell, JA Martenson, HS Wieand, JE Krook, JS Macdonald, DG Haller, RJ Mayer, LL Gunderson, TA Rich. <u>New England Journal of Medicine</u> 331(8):502-507, 1994.	GI	9/15/88	9/1/90
8906 (1039)	Hepatoma/merbarone: A Southwest Oncology Group study. EA Poplin, CM Tangen, WH Harvey, JS Macdonald. <u>Investigational New Drugs</u> 12:337-340, 1994.	GI	2/1/90	5/1/92
8917 (1035)	Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and roferon-A [®] : A Southwest Oncology study group study. ME Marshall, CM Tangen, JL Berenberg, SP Balcerzak, T Brown, JS Macdonald. <u>Cancer Biotherapy</u> 9(4):301-306, 1994.	GI	12/1/89	2/15/92
8936 (952)	Phase II trial of piroxantrone in gastric carcinoma: A Southwest Oncology Group study. A Hantel, C Tangen, WL Gluck, JS Macdonald. <u>Investigational New Drugs</u> 12(2):159-161, 1994.	GI	11/1/90	6/15/92
9006/9118 (1017)	Association of intratumoral pharmacokinetics of fluorouracil with clinical response. CA Presant, W Wolf, V Waluch, C Wiseman, P Kennedy, D Blayney, RR Brechner. <u>Lancet</u> 343:1184-1187, 1994.	GI		
9006/9118 (1018)	Measurement of human tumor pharmacokinetics in vivo noninvasively by 19-F magnetic resonance spectroscopy predicts clinical 5-FU sensitivity and resistance. CA Presant, W Wolf, V Waluch, R Brechner, C Wiseman, DW Blayney, P Kennedy. <u>Cancer Treatment, An Update</u> 757-758, 1994.	GI		
None (1008)	Gastric and esophageal cancers: Perspectives from a U.S. - Japan meeting. ML Rothenberg, M Fukushima, CA Coltman Jr. <u>Cancer Research and Clinical Oncology</u> 120:747-753, 1994.	GI		

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
7510 (954)	With > 4,600 patient-years follow-up, SWOG colorectal adjuvant study suggests that BCG may act as a chemoprevention agent. F Panettiére. <u>ASCO</u> 13:171 (#477), 1994.	GI	08/08/75	08/20/80
9006/9118 (1016)	Mechanism of 5-fluorouracil trapping in tumors - a possible model for a general process determining drug uptake. W Wolf, CA Presant, V Waluch. <u>American Association for Cancer Research</u> 35:432 (#2577), 1994.	GI		
*9217 (1009)	Chemoprevention of prostate cancer with finasteride, an Intergroup trial. CA Coltman Jr, P Feigl, IM Thompson. <u>Annals of Oncology</u> 5 (Suppl 8):65 (#P324), 1994.	GU	8/15/88	Open

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1993**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8040-8044 (508)	Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: A Southwest Oncology Group study. RM Bukowski, TR Fleming, JS Macdonald, N Oishi, SA Taylor, LH Baker. <u>Cancer</u> 71(2):322-325, 1993.	GI	01/28/81	03/16/84
8591 (INT-0035) (972)	Testing against ordered alternatives for censored survival data. PY Liu, S Green, M Wolf, J Crowley. <u>JASA</u> 88(421):153-160, 1993.	GI	01/14/85	10/01/87
8591 (INT-0035) (977)	An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. CG Moertel, TR Fleming, JS Macdonald, DG Haller, JA Laurie, C Tangen. <u>JAMA</u> 270(8):943-47, 1993.	GI	01/14/8	10/01/87
8591 (INT-0035) (1030)	Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. CG Moertel, TR Fleming, JS Macdonald, DG Haller, JA Laurie. <u>Journal of Clinical Oncology</u> 11(12):2386-2390, 1993.	GI	1/14/85	10/1/87
8614 (877)	VM-26 in gastric cancer: A Southwest Oncology Group Study. JL Berenberg, C Tangen, JS Macdonald, B Barlogie, LR Laufman. <u>IND</u> 11:333-334, 1993.	GI Dev Ther	10/15/88	9/15/90
8712 (453)	Phase II study of trimetrexate in previously untreated patients with hepatocellular carcinoma: A Southwest Oncology Group study. WH Harvey, TR Fleming, PJ Goodman, JE Harkins, SE Rivkin, JS Macdonald. <u>IND</u> 11:45-46, 1993.	GI Dev Ther	07/15/87	01/01/89
8714 (454)	Phase II trial of amonafide in advanced colorectal cancer: A Southwest Oncology Group study. TD Brown, PJ Goodman, T Fleming, JS Macdonald, JB Craig, AB Einstein. <u>Anti-Cancer Drugs</u> 4:49-50, 1993.	GI Dev Ther	03/01/89	05/01/89
8720 (879)	Phase II trial of amonafide in advanced pancreas cancer: A Southwest Oncology Group study. CG Leichman, C Tangen, JS Macdonald, T Leimert, TR Fleming. <u>IND</u> 11: 219-221, 1993.	GI Dev Ther	07/01/88	07/15/90
8730 (794)	Amonafide treatment of refractory esophageal cancer: A Southwest Oncology Group study. E Poplin, T Fleming, JS Macdonald, R Rodvien, K Grant, RI Fisher, ME Conrad. <u>IND</u> 11:47-51, 1993.	GI Dev Ther	11/01/90	04/15/92
8905 (971)	Selection designs for pilot studies based on survival. PY Liu, S Dahlberg, J Crowley. <u>Biometrics</u> 49:391-398, 1993.	GI	08/01/89	01/01/93
8916 (545)	Phase II trial of merbarone in pancreatic carcinoma: A Southwest Oncology Group study. EH Kraut, T Fleming, JS Macdonald, CH Spiridonidis, JE Bradof, LH Baker. <u>AJCO</u> 16(4):327-328, 1993.	GI Dev Ther	03/15/90	06/15/91

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8933 (891)	A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. TR Jenkins, C Tangen, JS Macdonald, G Weiss, R Chapman, A Hantel. <u>IND</u> 11:329-331, 1993.	GI	9/1/90	9/15/91
9006 (986)	Dynamic multinuclear chemical shift imaging of tumors (H-1, F-19, P-31) during 5-fluorouracil chemotherapy. H Kim, V Waluch, M Singh, CA Presant, W Wolf. <u>IEEE</u> 1316-1318, 1993.	GI	10/15/90	
ABSTRACTS PUBLISHED/PRESENTED				
8411 (673)	Phase II trial of DTIC in patients with metastatic carcinoid tumors: A Southwest Oncology Group study. A Bhatia, RF Peterson, C Tangen, T Fleming, J Macdonald, RM Bukowski. <u>ASCO</u> 12:222 (#677), 1993.	GI	07/20/84	02/15/88
*8572 (674)	Adjuvant continuous infusion 5FU (CI 5FU), whole abdominal radiation and tumor bed boost in Duke's C2 colon carcinoma: A Southwest Oncology Group pilot study. C Fabian, S Giri, N Estes, C Tangen, E Poplin, S Vogel, W Goodwin, T Fleming. <u>ASCO</u> 12:199 (#588), 1993.	GI	05/09/86	06/15/91
8591 (INT-0035) (675)	Recognition and salvage of the patient with recurrent colon cancer. C Moertel, T Fleming, J Macdonald, D Haller, J Laurie, C Tangen. <u>ASCO</u> 12:224 (#688), 1993.	GI	01/14/85	10/01/87
*8896 (INT-8647/51) (812)	Protracted venous infusion (PVI) 5-fluorouracil (5-FU) as a component of effective combined modality post-operative surgical adjuvant therapy for high-risk rectal cancer. M O'Connell, J Martenson, T Rich, H Wieand, J Krook, J Macdonald, D Haller, R Mayer, L Gunderson. <u>ASCO</u> 12:193 (#564), 1993.	GI	09/15/88	09/01/90
*8905 (679)	Fluorouracil (5-FU) schedules and modulation in advanced colorectal cancer (CRC): A Southwest Oncology Group screening trial. CG Leichman, TR Fleming, FM Muggia, B Ardan, J Doroshow, C Tangen, J Macdonald. <u>ASCO</u> 12:198 (#583), 1993.	GI	08/01/89	01/01/93
*9006/9118 (682)	Modulation of intratumoral (IT) 5FU pharmacokinetics (PK) by leucovorin (LV) and methotrexate (M) documented by 19F-magnetic resonance spectroscopy (MRS) - Initial results of Southwest Oncology Group studies 9006 and 9118. CA Presant, M Wolf, V Waluch, B Ardan, R Brechner, C Wiseman, DW Blayney, P Kennedy. <u>ASCO</u> 12:201 (#596), 1993.	GI		
*9135 (684)	A phase II trial of taxol and granulocyte colony stimulating factor (G-CSF) in patients with adenocarcinoma of the pancreas. T Brown, C Tangen, T Fleming, J Macdonald. <u>ASCO</u> 12:200 (#592), 1993.	GI	06/01/92	
Multiple Studies (859)	A new predictive PCR assay for detecting normal and malignant tissue thymidylate synthase (T.S.) gene expression in patients with 5-fluorouracil (5-FU) sensitive and resistant colorectal cancer. E Tian, KR Reddy, A Livingstone, B Ardan. <u>AACR</u> 34:387 (#2310), 1993.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1992**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8208 (778)	Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: A Southwest Oncology Group study. RM Bukowski, C Tangen, R Lee, JS Macdonald, AB Einstein, R Peterson, TR Fleming. <u>JCO</u> 10(12):1914-1918, 1992.	GI Dev Ther	12/01/82	02/15/88
8598 (INT-85-01) (526)	Combined chemotherapy and radiotherapy compared GI with radiotherapy alone in patients with cancer of the esophagus. A Herskovic, K Martz, M Al-Sarraf, L Leichman, J Brindle, V Vaitkevicius, J Cooper, R Byhardt, L Davis, B Emami. <u>NEJM</u> 326:1593-1598, 1992.		101/15/86	05/01/91
8755/8760 (539)	High incidence of coagulopathy in phase II studies of recombinant tumor necrosis factor (rTNF) in advanced pancreatic and gastric cancers. FM Muggia, TD Brown, PJ Goodman, EM Hersh, TR Fleming, L Leichman. <u>Anti-Cancer Drugs</u> 3(3):211-217, 1992.	GI Dev Bio		
8801 (464)	A Southwest Oncology Group phase I study of sequential combination of recombinant interferon-γ and recombinant interleukin-2 in patients with cancer. CW Taylor, EM Chase, JA Neidhart, JJ Rinehart, RP Whitehead, RC Gonzalez, PA Bunn, EM Hersh. <u>Journal of Immunotherapy</u> 3:176-183, 1992.	GI Dev Bio Dev Ther	10/01/88	01/01/90
ABSTRACTS PUBLISHED/PRESENTED				
*7804 (815)	A phase III trial of FAM (5-fluorouracil, adriamycin, mitomycin-C) chemotherapy vs control as adjuvant treatment for resected gastric cancer: A Southwest Oncology Group trial. JS Macdonald, R Gagliano, T Fleming, N Estes. <u>ASCO</u> 11:168 (#488), 1992.	GI	03/10/78	08/15/91
*8208 (817)	Phase II trial of 5-FU and chlorozotocin (CTZ) in patients with metastatic islet cell carcinoma. RM Bukowski, RF Peterson, PJ Goodman, C Tangen, J Macdonald. <u>ASCO</u> 11:168 (#486), 1992.	GI Dev Ther	12/01/82	02/15/88
*8591 (829)	The Intergroup study of fluorouracil (5-FU) plus levamisole (LEV) and levamisole alone as adjuvant therapy for stage C colon cancer. A final report. C Moertel, T Fleming, J Macdonald, D Haller, J Laurie. <u>ASCO</u> 11:161 (#457), 1992.	GI	01/14/85	10/01/87
*8721 (836)	A phase II trial of trimetrexate in the treatment of esophageal cancer: A Southwest Oncology Group trial. T Brown, T Fleming, C Tangen, J Macdonald. <u>ASCO</u> 11:166 (#479), 1992.	GI Dev Ther	09/01/87	09/01/91
9006 (988)	The use of MRS to monitor drug biodistribution, targeting and metabolism. W Wolf, CA Present, V Waluch. Presented at the <u>17th LH Gray Conference on Tumor Biology</u> , April 12-16, 1992.	GI	10/15/90	

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS
1991**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8424 (441)	A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin: A Southwest Oncology Group study. RP Whitehead, TR Fleming, JS Macdonald, FR Ahmann, HS Garewal, JP Kuebler. <u>IND</u> 9:345-347, 1991.	GI	12/07/84	05/01/87
8513 (396)	Phase II trial of menogaryl in adenocarcinoma of the pancreas: A Southwest Oncology Group study. T Brown, PJ Goodman, TR Fleming, LH Baker, JS Macdonald. <u>IND</u> 9:77-78, 1991.	GI	11/01/86	09/01/87
8622 (399)	Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study. TD Brown, PJ Goodman, TR Fleming, SA Taylor, JS Macdonald. <u>IND</u> 9:113-114, 1991.	GI	01/03/86	02/15/87
8630 (450)	Phase II trial of recombinant DNA gamma interferon in advanced colorectal cancer: A Southwest Oncology Group study. TD Brown, PJ Goodman, T Fleming, JS Macdonald, T O'Rourke, SA Taylor, JR Neefe, E Gaynor. <u>Journal of Immunotherapy</u> 10(5):379-382, 1991.	GI	05/15/87	11/15/88
8729 (492)	A phase II multi-institutional trial of low dose PALA and high dose 5-FU as a short term infusion in the treatment of adenocarcinoma of the pancreas: A Southwest Oncology Group study. LM Morrell, B Ardalan, SP Richman, P Goodman, TR Fleming, JS Macdonald. <u>Cancer</u> 67(2):363-366, 1991.	GI	03/01/88	01/01/90
8755 (463)	A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: A Southwest Oncology Group study. TD Brown, PJ Goodman, T Fleming, JS Macdonald, EM Hersh, TJ Braun. <u>Journal of Immunotherapy</u> 10:376-378, 1991.	GI	06/15/88	01/01/90
8800 (401)	Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study. EH Kraut, T Fleming, M Segal, JA Neidhart, BC Behrens, J Macdonald. <u>IND</u> 9:95-96, 1991.	GI	04/01/88	05/01/89

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*8598 (405)	Intergroup esophageal study: Comparison of radiotherapy (RT) to radio-chemotherapy combination: A phase III trial. A Herskovic, K Martz, M Al-Sarraf, L Leichman, JS Brindle, VK Vaitkevicius, J Cooper, R Byhardt, L Davis, B Emami. <u>ASCO</u> 10:135 (#407), 1991.	GI	10/15/86	05/01/91
*8896 (506)	Lack of value for metyl-CCNU (MeCCNU) as a component of effective rectal cancer surgical adjuvant therapy. Interim analysis of intergroup protocol 86-47-51. M O'Connell, H Wieand, J Krook, J Martenson, J Macdonald, T Rich, D Haller, R Mayer, L Gunderson. <u>ASCO</u> 10:134 (#403), 1991.	GI	09/15/88	09/01/90
None (422)	Multidrug resistance gene product (P-glycoprotein) expression as a marker for aggressive colon carcinomas. RS Weinstein, TM Grogan, JS Coon, IB Roninson. <u>U.S. & Canadian Academy of Pathology Lab Invest</u> 64:42A (#240), 1991.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1990**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8043 (301)	Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study. SA Taylor, T Fleming, DD Von Hoff, JD McCracken, RM Bukowski, RW Talley, RB Natale, JT Guy, WE Samlowski, JJ Costanzi. <u>IND</u> 8:77-80, 1990.	GI	01/28/81	08/17/84
8235 (309)	A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study. DD Von Hoff, PJ Goodman, CA Presant, RL Ruxer, JS Macdonald, JJ Costanzi, RL Stephens, SJ Vogel. <u>EJC</u> 26(3): 405-407, 1990.	GI	10/18/83	02/01/87
8237 (310)	5-day vinblastine infusion for pancreatic adenocarcinoma. A phase II Southwest Oncology Group study. JT Guy, T Fleming, TW Pollock, SE Rivkin, RP Pugh, H Saiers, HE Hynes, JF Boyd. <u>IND</u> 8:205-206, 1990.	GI	05/27/83	03/22/85
8373 (320)	Phase II trial of intravenous melphalan for metastatic colorectal carcinoma: A Southwest Oncology Group study. WA Knight, III, P Goodman, SA Taylor, JS Macdonald, CA Coltman, Jr, JJ Costanzi, LH Baker. <u>IND</u> 8:S87-S89, 1990.	GI	06/11/84	10/01/86
8404 (321)	Phase II evaluation of esorubicin (4' deoxydoxorubicin) in pancreatic adenocarcinoma: A Southwest Oncology Group study. CB Vaughn, SE Salmon, TR Fleming. <u>IND</u> 8:81-85, 1990.	GI	08/17/84	10/01/86
8426 (326)	VM-26 in colorectal carcinoma: A Southwest Oncology Group study. N Oishi, TR Fleming, L Laufman, JS Ungerleider, RB Natale, AB Einstein, Jr, DD Von Hoff, JS Macdonald. <u>IND</u> 8:93-95, 1990.	GI	01/14/85	10/01/86
8491	Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. JK Martin, Jr, MJ O'Connell, HS Wieand, RJ Fitzgibbons, Jr, JA Mailliard, J Rubin, DM Nagorney, LK Tschetter, JE Krook. <u>Archives of Surgery</u> 125:1022-1027, 1990.	GI	08/17/84	03/20/86
8565 (334)	A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study. RP Whitehead, RH Earhart, T Fleming, P Goodman, JS Macdonald, T Pollock, JS Ungerleider. <u>IND</u> 8:295-297, 1990.	GI	08/01/86	03/01/88

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8591 (335)	Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. CG Moertel, TR Fleming, JS Macdonald, DG Haller, JA Laurie, PJ Goodman, JS Ungerleider, WA Emerson, DC Tormey, JH Glick, MH Veeder, JA Mailliard. <u>NEJM</u> 322(6):352-358, 1990.	GI	01/14/85	10/01/87
8626 (342)	Phase II evaluation of recombinant interferon in patients with advanced pancreatic carcinoma: A Southwest Oncology Group study. DD Von Hoff, TR Fleming, JS Macdonald, PJ Goodman, J Van Damme, TD Brown, T O'Rourke, LG Feun, MD Keppen. <u>JBRM</u> 9:584-587, 1990.	GI	05/15/87	11/15/88
8743 (344)	A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: A Southwest Oncology Group study. RP Whitehead, T Fleming, JS Macdonald, PJ Goodman, J Neefe, TJ Braun, LJ Swinnen, EM Hersh. <u>JBRM</u> 9:588-591, 1990.	GI	06/15/88	01/01/90
ABSTRACTS PUBLISHED/PRESENTED				
*8743 (371)	A phase II study of recombinant tumor necrosis factor (rTNF) in patients with metastatic colorectal adenocarcinoma. A Southwest Oncology Group study. RP Whitehead, T Fleming, P Goodman, J Neefe, TJ Braun, LJ Swinnen, EM Hersh. <u>ASCO</u> 9:106 (#411), 1990.	GI	06/15/88	01/01/90
8755 (372)	Recombinant tumor necrosis factor (rTNF) intolerance in pancreatic and gastric cancers: A Southwest Oncology Group trial. FM Muggia, T Brown, P Goodman, L Leichman, J Macdonald, EM Hersh. <u>AACR</u> 31:185 (#1102), 1990.	GI	06/15/88	01/01/90
8800 (374)	Phase II trial of pibenzimol in advanced pancreatic carcinoma. A Southwest Oncology Group study. E Kraut, J Neidhart, J Macdonald. <u>ASCO</u> 9:130 (#504), 1990.	GI	04/01/88	05/01/89

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1989**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8233	Phase II study of diaziquone in untreated advanced gastric carcinoma: A Southwest Oncology Group study. RP Pugh, T Fleming, JT Guy, JK Weick, JH Ward. <u>AJCO</u> (CCT) 12(1):11-13, 1989.	GI	10/18/83	12/15/86
ABSTRACTS PUBLISHED/PRESENTED				
7510	After resection of large bowel carcinoma, immune status is often depressed. Data from a SWOG study. FJ Panettiere. <u>ASCO</u> 8:107 (#415), 1989.	GI	08/08/75	08/20/80
*8390	5-fluorouracil (5-FU) and folinic acid (FA) for the treatment of metastatic gastric cancer. JL Berenberg, PJ Goodman, N Oishi, T Fleming, RB Natale, LH Hutchins, GT Guy, J Macdonald. <u>ASCO</u> 8:101 (#392), 1989.	GI	03/16/84	03/01/88
8424	A phase II study of 5-fluorouracil (5-FU) plus cisplatin (P) for metastatic colorectal adenocarcinoma: A Southwest Oncology Group study. RP Whitehead, T Fleming, JS Macdonald, F Ahmann, M Inamasu. <u>ASCO</u> 8:128 (#498), 1989.	GI	12/07/84	05/01/87
*8491	A controlled trial of regional intra-arterial FUDR versus systemic 5-FU for the treatment of metastatic colorectal cancer confined to the liver. M O'Connell, J Mailliard, J Martin, R Fitzgibbons, D Nagorney, H Wieand, L Tschetter, J Krook. <u>ASCO</u> 8:98 (#379), 1989.	GI	08/17/84	03/20/86
*8491	Mayo Clinic and North Central Cancer Treatment Group (NCCTG) experience with intra-arterial chemotherapy for colorectal cancer liver metastases. MJ O'Connell. Presented at <u>EORTC</u> Symposium Strasbourg, France, Nov. 15-17, 1989.	GI	08/17/84	03/20/86
8513	Phase II trial of menogaril in advanced pancreatic carcinoma: A Southwest Oncology Group trial. T Brown, L Baker, P Goodman, T Fleming, G Fries, J Macdonald. <u>ASCO</u> 8:124 (#481), 1989.	GI	01/03/86	02/15/87
8565	A phase II study of menogaril (NSC 269148) in colorectal carcinoma: A Southwest Oncology Group study. RP Whitehead, RH Earhart, P Goodman, JS Macdonald, T Pollock, JS Ungerleider. <u>ASCO</u> 8:117 (#453), 1989.	GI	08/01/86	03/01/88

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
8630	Randomized phase II trial of recombinant gamma interferon administered on two schedules in advanced colorectal cancer: A Southwest Oncology Group trial. T Brown, T Fleming, P Goodman, J Macdonald. <u>ASCO</u> 8:124 (#482), 1989.	GI	05/15/87	11/15/88

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1988**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7510	Adjuvant therapy in large bowel adenocarcinoma: Long-term results of a Southwest Oncology Group study. FJ Panetti, PJ Goodman, JJ Costanzi, AB Cruz, Jr, VK Vaitkevicius, JD McCracken, RW Brownlee, L Laufman, RL Stephens, J Bonnet, R Bottomley, S Rivkin, W Fletcher, N Oishi, TT Chen. <u>JCO</u> 6(6):947-954, 1988.	GI	08/08/75	08/20/80
8263	Phase I-II pilot of whole abdominal radiation and concomitant 5-FU as an adjuvant in colon cancer: A Southwest Oncology Group study. CJ Fabian, E Reddy, W Jewell, AA Trowbridge, JD McCracken, S Vogel, JW Goodwin, WS Fletcher. <u>International Journal of Radiation Oncology Biology Biophysics</u> , 15:885-892, 1988.	GI	07/09/82	10/01/86
ABSTRACTS PUBLISHED/PRESENTED				
8611	A randomized trial of two schedules of trimetrexate (TMTX) versus 5-fluorouracil (5 FU) in colorectal carcinoma: A Southwest Oncology Group study. T Brown, T Fleming, J Macdonald. <u>ASCO</u> 7:109 (#419), 1988.	GI	01/15/87	11/15/88

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1987**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8017	A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors: A Southwest Oncology Group study. RM Bukowski, KG Johnson, RF Peterson, RL Stephens, SE Rivkin, B Neilan, JJ Costanzi. <u>Cancer</u> 60(12):2891-2895, 1987.	GI	07/07/80	01/19/84
8037	Combined therapies for squamous-cell carcinoma of the esophagus. A Southwest Oncology Group study. E Poplin, T Fleming, L Leichman, HG Seydel, Z Steiger, S Taylor, R Vance, WJ Stuckey, SE Rivkin. <u>JCO</u> 5(4): 622-628, 1987.	GI	02/16/81	01/19/84
8044	Phase II evaluation of diaziquone in pancreatic carcinoma: A Southwest Oncology Group study. EJ Tilchen, T Fleming, G Mills, N Oishi, JD Bonnett, RB Natale, G Harker, CA Coltman, Jr. <u>Cancer Treat Rep</u> 71(12):1309-1310, 1987.	GI	05/27/83	08/17/84
8119	Phase II trial of bisantrene in hepatocellular carcinoma: A Southwest Oncology Group study. TD Brown, TR Fleming, RA Shildt, JD Cowan. <u>Cancer Treat Rep</u> 71(11):1101-1102, 1987.	GI	02/22/82	03/22/85
8218	Therapy for advanced renal cell cancer with spiro-germanium: A Southwest Oncology Group study. JH Saiers, M Slavik, RL Stephens, ED Crawford. <u>Cancer Treat Rep</u> 71(2):207-208, 1987.	GI	02/16/81	01/19/84
8277	Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma: A Southwest Oncology Group pilot study. RM Bukowski, A Theodors, JD Purvis, GT Budd, JK Weick, R Gahbauer. <u>AJCO</u> 10(5):376-379, 1987.	GI	02/18/83	10/03/84
8305	5-fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: A randomized comparison. A Southwest Oncology Group study. GT Budd, TR Fleming, RM Bukowski, JD McCracken, SE Rivkin, RM O'Bryan, SP Balcerzak, JS Macdonald. <u>JCO</u> 5(2):272-277, 1987.	GI	05/27/83	03/16/84
8311	Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: A Southwest Oncology Group study. R Chapman, TR Fleming, J Van Damme, J Macdonald. <u>Cancer Treat Rep</u> 71(12):1185-1187, 1987.	GI	07/26/83	03/22/85
8318	Phase II study of fludarabine phosphate in previously untreated patients with hepatoma: A Southwest Oncology Group study. WH Harvey, TR Fleming, G Beltran, JH Saiers, N Oishi, DD Von Hoff. <u>Cancer Treat Rep</u> 71(11):1111-1112, 1987.	GI	07/20/84	10/01/86

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

8386	Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: A Southwest Oncology Group study. WH Harvey, TR Fleming, DD Von Hoff, JG Katterhagen, CA Coltman, Jr. <u>Cancer Treat Rep</u> 71(12):1319-1320, 1987.	GI	01/19/84	03/22/85
------	---	----	----------	----------

ABSTRACTS PUBLISHED/PRESENTED

Multiple Studies	Phase II trial of continuous infusion cytarabine (ARA-C) and bolus cis-platin (CDDP) in advanced solid tumors: renal, gastric, esophageal, pancreatic, and unknown primary cancers. L Leong, J Doroshow, S Akman, B Carr, D Goldberg, K Margolin. <u>ASCO</u> #C-549, 1987.	GI
---------------------	---	----

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1986**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
8042	Phase II study of mitoguazone in pancreatic cancer: A Southwest Oncology Group study. MS Inamasu, N Oishi, TT Chen, EH Kraut, PN Grozea, JJ Costanzi, JD Bonnet. <u>Cancer Treat Rep</u> 70(4):531-532, 1986.	GI	01/28/81	05/05/82
8120	Bisantrene hydrochloride in gastric adenocarcinoma: A Southwest Oncology Group study. FJ Panettiére, SE Jones, N Oishi, HJ Eyre, RM O'Bryan, WA Andes, SA Taylor, PN Grozea. <u>Medical and Pediatric Oncology</u> 14:78-80, 1986.	GI	02/22/82	03/16/84
ABSTRACTS PUBLISHED/PRESENTED				
7510	The prognosis of exophytic large bowel tumors. Data from a Southwest Oncology Group adjuvant study. F Panettiére, AR Rogers, and the University of Arkansas Medical Science Campus. <u>ASCO</u> , #C-306, 1986.	GI	08/08/75	08/20/80

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1985**

NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7910	Tamoxifen therapy and colorectal adenocarcinoma. A Southwest Oncology Group study. FJ Panettiere, CW Groppe, JW Athens, JJ Costanzi, JD Bonnet, JH Saiki, TT Chen. <u>Cancer Treat Rep</u> 69:113-114, 1985.	GI	04/18/79	04/14/81
7931	Phase II study of amsacrine in gastric carcinoma: A Southwest Oncology Group study. M Inamasu, N Oishi, TT Chen, WJ Hicks, RM O'Bryan. <u>Cancer Treat Rep</u> 69(5):557-558, 1985.	GI	10/05/79	04/14/81
8066	Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic radiation in high-risk patients with carcinoma of the colon. A Southwest Oncology Group phase II pilot study. JD McCracken, TJ Weatherall, N Oishi, L Janaki, C Boyer. <u>Cancer Treat Rep</u> 69:129-131, 1985.	GI	08/25/80	03/30/83
8360	The implanted pump in metastatic colorectal cancer of the liver. LP Johnson, SE Rivkin. <u>Am J Surg</u> 149:595-598, 1985.	GI	02/18/83	03/16/84
ABSTRACTS PUBLISHED/PRESENTED				
*7510	SWOG large bowel adjuvant study suggests benefits from therapy. FJ Panettiere, TT Chen. <u>ASCO</u> , #C-295, 1985.	GI	08/08/75	08/20/80
8040/42/43	Randomized trials of combination chemotherapy vs. a Phase II drug in metastatic adenocarcinoma of the pancreas: Southwest Oncology Group study. RM Bukowski, M Inamasu, S Taylor, T Chen. <u>ASCO</u> , #C-311, 1985.	GI		
8263	Phase I study of whole abdominal XRT plus concomitant bolus 5-FU as adjuvant therapy in Duke's B2C colon cancer: A Southwest Oncology Group study. C Fabian, E Reddy, W Jewell, A Trowbridge. <u>ASCO</u> , #C-331, 1985.	GI	07/09/82	10/01/86
8305	A randomized comparison of 2 dose-schedules of 5-Fluorouracil (5FU) and folinic acid (FA) for the treatment of metastatic colorectal cancer. GT Budd, R Bukowski, T Fleming, P McCracken. <u>ASCO</u> , #C-318, 1985.	GI	05/27/83	03/16/84
8360	The use of the surgically implanted "Infusaid" pump for ambulatory outpatient hepatic arterial chemotherapy for analysis 5-FUDR and combined 5-FUDR and cisplatinium. SE Rivkin, L Johnson. <u>ASCO</u> , #C-322, 1985.	GI	02/18/83	03/16/84

8386	Evaluation of fludarabine phosphate (FAMP) in colorectal carcinoma. A Southwest Oncology Group Phase II study. WH Harvey, DD Von Hoff, JG Katterhagen, DL Kisner. <u>ASCO</u> , #C-351, 1985.	GI	01/19/84	03/22/85
------	---	----	----------	----------

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1984**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7639	Drug combinations in the treatment of gastric adenocarcinoma: A Southwest Oncology Group study. FJ Panettiére, C Haas, B McDonald, JJ Costanzi, RW Talley, J Athens, N Oishi, LK Heilbrun, TT Chen. <u>J Clin Oncol</u> 2:420-424, 1984.	GI		
7806	Chemotherapy of advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: Final report on a Southwest Oncology Group study. FJ Panettiére, LP Leichman, EJ Tilchen, TT Chen. <u>Cancer Treat Rep</u> 68:1023-1024, 1984.	GI		
7833	Chlorozotocin: Results in colorectal carcinoma treated with high and low doses. A Southwest Oncology Group study. CD Haas, JD McCracken, CB Vaughn, RL Stephens, RM Bukowski, HJ Eyre. <u>Invest New Drugs</u> 2:401-404, 1984.	GI		
7931	Phase II trial of amsacrine in pancreatic carcinoma: A Southwest Oncology Group study. M Inamasu, N Oishi, T Chen, S Legha, J McCracken, S Balcerzak, R Stephens, R O'Bryan, SE Rivkin, JJ Costanzi, RB Natale, LH Baker, CA Colman Jr. <u>Cancer Treat Rep</u> 68:1411-1412, 1984.	GI		

ABSTRACTS PUBLISHED/PRESENTED

*7510	SWOG large bowel postoperative program. An update. FJ Panettiére, TT Chen. <u>4th International Conference on the Adjuvant Therapy of Cancer</u> (Tucson, March 1984), 94, 1984.	GI		
*7738/8040	Characteristics of long term survivors receiving chemotherapy for pancreatic adenocarcinoma in Southwest Oncology Group (SWOG) studies. RM Bukowski. <u>ASCO</u> , #C-583, 1984.	GI		
7969	Hepatic artery infusion (HAI) with 5FUDR (F), Adriamycin (A) and Streptozotocin (ST) in unresectable hepatoma. A Southwest Oncology Group study. R Shildt, L Baker, W Stuckey. <u>ASCO</u> , #C-587, 1984.	GI		
8037	Pre-operative adjuvant therapy for squamous cell cancer (SCC) of the esophagus: SWOG & RTOG clinical trials. L Leichman, HG Seydel, Z Steiger. <u>ASCO</u> , #C-575, 1984.	GI		
8120	Bisantrene hydrochloride in gastric adenocarcinoma. A SWOG study. FJ Panettiére. <u>AACR</u> , #688, 1984.	GI		
8206	Phase II trial of Aclacinomycin A in advanced colorectal cancer using two dosage schedules: A Southwest Oncology Group study. FE Bull, LH Baker, JD Bonnet, DO Dixon. <u>ASCO</u> , #C-581, 1984.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1983**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7717	Management of patients with metastatic adenocarcinoma of unknown origin: A Southwest Oncology Group study. RA Shildt, PS Kennedy, TT Chen, JW Athens, RM O'Bryan, SP Balcerzak. <u>Cancer Treat Rep</u> 67:77-79, 1983.	GI		
7738	Randomized trial of 5-Fluorouracil and Mitomycin C with or without Streptozotocin for advanced pancreatic cancer. RM Bukowski, SP Balcerzak, RM O'Bryan, JD Bonnet, TT Chen. <u>Cancer</u> 52:1577-1582, 1983.	GI		
7864	Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, Doxorubicin, and Mitomycin for residual localized gastric adenocarcinoma: A Southwest Oncology Group pilot study. CD Haas, CM Mansfield, LP Leichman, B Considine, RM Bukowski. <u>Cancer Treat Rep</u> 67:421-424, 1983.	GI		
7920	Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: A Southwest Oncology Group study. RM Bukowski, LP Leichman, SE Rivkin. <u>Eur J Cancer Clin Oncol</u> 19:721-723, 1983.	GI		
7935	Phase II study of Chlorozotocin in islet cell carcinoma: A Southwest Oncology Group study. RM Bukowski, JD McCracken, SP Balcerzak, CJ Fabian. <u>Cancer Chemother Pharmacol</u> 11:48-50, 1983.	GI		
*8108/16/ 17/18/19/ 20/61/ 8214	Southwest Oncology Group studies with Bisantrene. CA Coltman Jr, D Cowan, DD Von Hoff, GM Durie, TP Miller, E Surwit, DS Alberts, RA Shildt, F Panetiere, GM Mills, PB Wasserman, TM McDaniel. In: <u>13th International Congress of Chemotherapy</u> (Vienna, August 28-September 2, 1983). KH Spitzzy, K Karrer, eds. <u>Symposium Bisantrene</u> 213:1-4, 1983.	Myeloma, Lymphoma, GYN, GI, Melanoma, Leukemia, Sarcoma		

ABSTRACTS PUBLISHED/PRESENTED

*7510	The SWOG large bowel adjuvant program. An update. FJ Panettiere, TT Chen. <u>ASCO</u> , #C-455, 1983.	GI
7804	Adjuvant chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin (FAM) in gastric cancer - A SWOG study. R Gagliano, JD McCracken, T Chen. <u>ASCO</u> , #C-443, 1983.	GI
*7841	Southwest Oncology Group Phase II-III gastric cancer study: 5-Fluorouracil, Adriamycin, and Mitomycin-C + Vincristine (FAM vs V-FAM) compared to chlorozotocin (CZT), m-AMSA, and Dihydroxyanthracenedione (DHAD) with unimpressive differences. C Haas, N Oishi, B McDonald, C Coltman, R O'Bryan. <u>ASCO</u> , #C-478, 1983.	GI
*7940	Evaluation of 5-FU vs. a Phase II drug in metastatic adenocarcinoma of the large bowel: Southwest Oncology Group (SWOG) study 7940. L Leichman, C Fabian, R O'Bryan, JT Guy, W Fletcher, R Shildt, JD McCracken, T Chen. <u>ASCO</u> , #C-469, 1983.	GI
7945	AZQ in the treatment of colon cancer - A Southwest Oncology Group study. R Shildt, J Bonnet, W Fletcher. <u>ASCO</u> , #C-496, 1983.	GI
*8017	Phase II trial of 5FU, Adriamycin, Cyclophosphamide, and Streptozotocin (FAC-S) in metastatic carcinoid (for the Southwest Oncology Group). RM Bukowski, R Stephens, N Oishi, R Petersen, T Chen. <u>ASCO</u> , #C-510, 1983.	GI

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1982**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7510	The SWOG colon adjuvant study of chemotherapy with and without oral BCG: An update. FJ Panetiere, TT Chen. In: <u>Immunotherapy of Cancer</u> . WD Terry, SA Rosenberg, eds. New York: Elsevier-North Holland, pp. 207-215, 1982.	GI		
7735	Phase II study of Anguidine in gastrointestinal malignancies: A Southwest Oncology Group study. R Bukowski, C Vaughn, R Bottomley, TT Chen. <u>Cancer Treat Rep</u> 66:381-383, 1982.	GI		
7861	Radiation therapy combined with intra-arterial 5-FU chemotherapy for the treatment of localized adenocarcinoma of the pancreas. JD McCracken, M Olson, AB Cruz, L Leichman, N Oishi. <u>Cancer Treat Rep</u> 66:549-551, 1982.	GI		
7920	Phase II trial of m-AMSA in hepatocellular carcinoma: A Southwest Oncology Group study. RM Bukowski, S Legha, J Saiki, HJ Eyre, R O'Bryan. <u>Cancer Treat Rep</u> 66:1651-1652, 1982.	GI		
7940/41	Methyl-GAG in advanced colon cancer: A Phase II trial of the Southwest Oncology Group. WA Knight III, DM Loesch, LP Leichman, C Fabian, RM O'Bryan. <u>Cancer Treat Rep</u> 66:2099-2100, 1982.	GI		
7940/44	Phase II trial of Mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group study. JD Cowan, DD Von Hoff, B McDonald, RW Talley, JD McCracken, T Chen. <u>Cancer Treat Rep</u> 66:1779-1780, 1982.	GI		
ABSTRACTS PUBLISHED/PRESENTED				
None	Direct cloning of human adenocarcinoma of the colon in soft agar: Relationship to Duke's stage at time of diagnosis and degree of differentiation. DM Loesch, D Von Hoff, and the Southwest Oncology Group. <u>ASCO</u> , #P-29, 1982.	GI		
*7510	Long-term hematologic effects of Methyl-CCNU plus 5-FU given in a Southwest Oncology Group adjuvant study. FJ Panetiere. <u>AACR</u> , #587, 1982.	GI		
*7910	Southwest Oncology Group trial of Tamoxifen in patients with advanced colorectal adenocarcinoma. FJ Panetiere, TT Chen. <u>ASCO</u> , #C-364, 1982.	GI		

7931	A Phase II evaluation of m-AMSA in advanced gastric and pancreatic carcinoma: A Southwest Oncology Group study. M Inamasu, J McCracken, S Legha, T Chen, R Stephens, R Bukowski, R O'Bryan, N Oishi, CA Coltman Jr. <u>ASCO</u> , #C-389, 1982.	GI
7935	Chemotherapy of islet cell carcinoma with Chlorozotocin (CTZ): A Southwest Oncology Group study. RM Bukowski. <u>Clin Res</u> 30:415A, 1982.	GI
*7935	Chemotherapy of islet cell carcinoma with Chlorozotocin (CTZ): A Southwest Oncology Group study. RM Bukowski. <u>ASCO</u> , #C-349, 1982.	GI
7940/44	Phase II evaluation of Mitoxantrone in previously untreated patients with colorectal cancer. J Cowan, DD Von Hoff, B McDonald, R Talley, J McCracken. <u>ASCO</u> , #C-385, 1982.	GI
8066	Adjuvant intrahepatic chemotherapy with Mitomycin-C and 5-FU combined with hepatic radiation in high risk patients with carcinoma of the lung. JD McCracken, T Weatherall, N Oishi. <u>UICC</u> , #03963, 1982.	GI

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1981**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7510	Letter to the Editor: IgA antibody-dependent cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma. FJ Panettiere. <u>Int J Cancer</u> 27:865, 1981.	GI		
7510	Analysis of 626 patients entered on the SWOG large bowel adjuvant program. FJ Panettiere, TT Chen. In: <u>Adjuvant Therapy of Cancer III</u> . SE Salmon and SE Jones, eds. Grune and Stratton, 539-545, 1981.	GI		
7801	Therapy for advanced colorectal cancer with a combination of 5-Fluorouracil and Anguidine. W Goodwin, R Stephens, JD McCracken, C Groppe. <u>Cancer Treat Rep</u> 65:359, 1981.	GI		
7806	Cis-diamminedichloride platinum (II), an effective agent in the treatment of epidermoid carcinoma of the esophagus. A preliminary report of an ongoing Southwest Oncology Group study. FJ Panettiere, L Leichman, R O'Bryan, C Haas, W Fletcher. <u>Cancer Clin Trials</u> 4:29-31, 1981.	GI		
7860	Phase I-II trial of Methyl-GAG in advanced colon cancer: A Southwest Oncology Group pilot study. JW Myers, WA Knight III, RB Livingston, CJ Fabian, J Costanzi. <u>Cancer Clin Trials</u> 4:277-279, 1981.	GI		

ABSTRACTS PUBLISHED/PRESENTED

7510	Update on the Southwest Oncology Group Colorectal Adjuvant study of 620 patients. FJ Panettiere, TT Chen. <u>ASCO</u> , #C-82, 1981.	GI		
7629/7806/ 7807	Cis-platinum (CACP) toxicity. An analysis based on 3 Southwest Oncology Group studies. FJ Panettiere. <u>AACR</u> , #623, 1981.	Head & Neck, GI, Lung		
7738	Randomized comparison of 5-FU and Mitomycin-C (MF) versus 5-FU, Mitomycin-C and Streptozotocin (SMF) in pancreatic adenocarcinoma. A Southwest Oncology Group study. RM Bukowski. <u>ASCO</u> , #C-472, 1981.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1980**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7509	5-Fluorouracil, Methyl-CCNU and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: A Southwest Oncology Group study. JD McCracken, P Ray, L Heilbrun, V Vaitkevicius, J Saiki, S Rivkin, A Rossof, T Moore. <u>Cancer</u> 46:1518-1522, 1980.	GI		
ABSTRACTS PUBLISHED/PRESENTED				
7510	The SWOG Colon Adjuvant Study of chemotherapy with and without oral BCG - an update. FJ Panettiere, TT Chen. <u>Immunotherapy of Cancer: Present Status of Trials in Man</u> , p. 16, April, 1980.	GI		
7510	Long-term effects of chemotherapy on leukocytes of clinically healthy patients treated in accordance with the Southwest Oncology Group Colon Adjuvant Protocol. FJ Panettiere. <u>AACR</u> , #618, 1980.	GI		
7510	Adjuvant chemotherapy with or without immunotherapy in colorectal cancer. FJ Panettiere. <u>Clin Res</u> 28(15), 1980.	GI		
7639	Southwest Oncology Group experience with two different schedules of 5-FU, Adriamycin and Mitomycin C (FAM) in the management of gastric carcinoma. FJ Panettiere, LK Heilbrun. <u>American College of Physicians Air Force Regional Meeting</u> , 46, 1980.	GI		
7735	Anguidine in gastrointestinal malignancies: Southwest Oncology Group Phase II Study. RM Bukowski, CB Vaughn, J Hampton, WJ Stuckey. <u>ASCO</u> , #C-133, 1980.	GI		
7830	Design and implementation of a clinical trial of carcinoembryonic antigen as an indicator for second-look surgery in colorectal cancer. DC Young, JP Minton. <u>Society for Clinical Trials</u> , #26, 1980.	GI		
7860	Methyl-Glyoxal Bis-Guanylhydrazone (Methyl-GAG, MGBG) in advanced colon carcinoma. WA Knight III, RB Livingston, JJ Costanzi, RE Paque. <u>AACR</u> , #656, 1980.	GI		
7864	Southwest Oncology Group Pilot study of radiotherapy (R) + 5-Fluorouracil (F) + Adriamycin (A) + Mitomycin-C (M) in patients (PTS) with minimal residual gastric cancer (MRGC). C Haas, V Vaitkevicius, R Bukowski, D Moore, C Mansfield. <u>ASCO</u> , #C-91, 1980.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1979**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7434	5-FU infusion with Mitomycin-C vs. 5-FU infusion with Methyl-CCNU in the treatment of advanced upper gastrointestinal cancer. A Southwest Oncology Group study. T Buroker, P Kim, C Groppe, J McCracken, R O'Bryan, F Panettiere, J Costanzi, R Bottomley, G King, J Bonnet, T Thigpen, J Whitecar, C Haas, V Vaitkevicius, B Hoogstraten, L Heilbrun. <u>Cancer</u> 44(4):1215-1221, 1979.	GI		
7434	The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treatment with chemotherapy. A Southwest Oncology Group study. M Al-Sarraf, L Baker, RW Talley, K Kithier, V Vaitkevicius. <u>Cancer</u> 44:1222-1225, 1979.	GI		
7438	Phase II evaluation of cis-dichlorodiammineplatinum (II) in advanced malignancies of the genitourinary and gynecologic organs: A Southwest Oncology Group study. A Rossof, R Talley, R Stephens, T Thigpen, M Samson, C Groppe, Jr, H Eyre, R Fisher. <u>Cancer Treat Rep</u> 63(9-10):1557-1564, 1979.	GI GYN		
7510	Effectiveness of post-operative adjuvant therapy with methyl-CCNU plus 5-FU with or without oral BCG in an attempt to prevent recurrence of Duke B-2 or C colon cancer. Interim report of a continuing SWOG study. FJ Panettiere, L Heilbrun. In: <u>Adjuvant Therapy of Cancer II</u> , Grune and Stratton, Inc., pp. 595-602, 1979.	GI		
7619	Phase II evaluation of Ftorafur in previously untreated colorectal cancer. A Southwest Oncology Group study. T Buroker, F Padilla, C Groppe, G Guy, J Quagliana, J McCracken, VK Vaitkevicius, B Hoogstraten, L Heilbrun. <u>Cancer</u> 44(1):48-51, 1979.	GI		
7639	Experiences with two treatment schedules in the combination chemotherapy of advanced gastric carcinoma. FJ Panettiere, L Heilbrun. In: <u>Mitomycin-C - Current Status and New Developments</u> , Chapter 16:145-157, 1979.	GI		
7860	Phase I-II trial of Methyl-GAG: A Southwest Oncology Group pilot study. WA Knight III, RB Livingston, C Fabian, J Costanzi. <u>Cancer Treat Rep</u> 63(11-12):1933-1937, 1979.	GI		

ABSTRACTS PUBLISHED/PRESENTED

7495/7693	Multiagent chemotherapy for primary liver tumors in children. Evans et al. 1979.	GI
7509	5-FU, Methyl-CCNU and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas. J McCracken, P Ray, V Vaitkevicius, L Heilbrun, A Rossof. <u>ASCO</u> , #C-260, 1979.	GI
7510	Race and chemotherapy-induced marrow suppression. F Panettiere. <u>Clinical Research</u> 27:745A, 1979.	GI
*7510	Are there racial differences in chemotherapy-induced leukocyte suppression. F Panettiere. <u>AACR</u> , 1979.	GI
7510	Effectiveness of postoperative adjuvant therapy with Methyl CCNU + 5-FU with or without oral BCG in an attempt to prevent recurrence of Duke B ₂ or C Colon cancer, interim report of continuous SWOG studies. F Panettiere, L Heilbrun. <u>International Conference on the Adjuvant Therapy of Cancer</u> #63, 1979.	GI
7634	Evaluation of BTdGR (B) with either Methyl-CCNU (Me) or Mitomycin C (Mi) in the management of disseminated colorectal carcinoma. FJ Panettiere, R Gagliano, L Heilbrun. <u>AACR</u> , #277, 1979.	GI
7639	Comparison of two different combination of Adriamycin, mitomycin-C and 5-FU in the treatment of gastric carcinoma. F Panettiere, L Heilbrun. <u>ASCO</u> , #C-102, 1979.	GI
7860	Methyl-Glyoxal-Bis-Guanyldrazone (Methyl-GAG, MGBG) in advanced human malignancy. W Knight, R Rivingston, C Fabian, J Costanzi. <u>ASCO</u> , #C-115, 1979.	GI
*7861	Intra-arterial 5-FU chemotherapy combination with radiotherapy for the treatment of localized adenocarcinoma of the pancreas. J McCracken, A Cruz, N Oishi, V Vaitkevicius. <u>American Pancreatic Association Natl Pancreatic Cancer Project</u> , Presented 1979.	GI

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1978**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7434	5-FU infusion with mitomycin-C versus 5-FU infusion with methyl-CCNU in the treatment of advanced colon cancer. T Buroker, PN Kim, C Groppe, J Mccracken, R O'Bryan, F Panettiere, CA Coltman, Jr, R Bottomley, H Wilson, J Bonnet, T Thigpen, VK Vaitkevicius, B Hoogstraten, L Heilburn. <u>Cancer</u> 42(3):1228-1233, 1978.	GI		
7512	Phase II study of Baker's antifol in advanced colorectal cancer. F Padilla, J Correa, T Buroker, VK Vaitkevicius. <u>Cancer Treat Rep</u> 62(4):553, 1978.	GI		
ABSTRACTS PUBLISHED/PRESENTED				
7510	Postoperative adjuvant chemotherapy and immunotherapy after total clinical resection of Duke C large bowel cancer: A Southwest Oncology Group study. FJ Panettiere, L Heilbrun. <u>XIIth International Cancer Congress</u> , Buenos Aires, Argentina, Vol. 2:256-257, 1978.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1977**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
MANUSCRIPTS PUBLISHED/PRESENTED				
7430	Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. LH Baker, JH Saiki, SE Jones, JS Hewlett, RW Brownlee, RL Stephens and VK Vaitkevicius. <u>Cancer Treat Rep</u> 61:1595-97, 1977.	GI		
7510	Adjuvant therapy for locally advanced large bowel cancer. FJ Panetiere. In: <u>Adjuvant Therapy of Cancer</u> , Salmon, S.E., and Jones, S. (eds), Elsevier/North Holland, pp. 265-272, 1977.	GI		
ABSTRACTS PUBLISHED/PRESENTED				
7434	5-FU infusion with mitomycin-C vs. 5-FU infusion with methyl CCNU in the treatment of advanced colon cancer. T Buroker, PN Ki, L Heilbrun and VK Vaitkevicius. <u>ASCO</u> , #C-18, 1977.	GI		
7510	Skin test reactivity in patients with high-risk but clinically totally resected large bowel cancer. FJ Panetiere. <u>AACR</u> , #454, 1977.	GI		
7510	Adjuvant chemotherapy and chemoimmunotherapy for locally advanced large bowel adenocarcinoma. Preliminary report of a SWOG study. FJ Panetiere. <u>Proc. Intl. Conference on the Adjuvant Therapy of Cancer</u> in Tucson, AZ, #31, 1977.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1976**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

7302	Phase III comparison of the treatment of advanced gastro-intestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. LH Baker, RW Talley, R Matter, DE Lehane, BW Ruffner, SE Jones, FS Morrison, RL Stephens, EA Gehan, VK Vaitkevicius. <u>Cancer</u> 38(7):1-7, 1976.	GI		
7302	Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer. LH Baker, VK Vaitkevicius, EA Gehan, and Gastrointestinal Committee of the Southwest Oncology Group. <u>Cancer Treat Rep</u> 60(6):733-737, 1976.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1975**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
ABSTRACTS PUBLISHED/PRESENTED				
*7302	5-fluorouracil and 1-(2-Chloroethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea in gastrointestinal cancers. LH Baker, R Matter, RW Talley and F Vaitkevicius. <u>ASCO</u> , #1034, 1975.	GI		

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1972**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Combined 5-fluorouracil and vinblastine therapy for gastrointestinal and other solid tumors. M Al-Sarraf, CB Vaughn, ML Reed and VK Vaitkevicius. <u>Oncology</u> 26:99-113, 1972.	GI		
---	--	----	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1970**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Primary malignant tumors of the small intestine. EL Reyes, RW Talley. <u>American Journal of Gastroent</u> 54(1):30-43, 1970.	GI		
---	---	----	--	--

**SOUTHWEST ONCOLOGY GROUP
PUBLICATIONS LIST
1964**

PROTOCOL NUMBER	PUBLICATIONS (TITLE & CITATION)	DISEASE	DATE PROTOCOL ACTIVATED	DATE PROTOCOL CLOSED TO PATIENT ENTRY
--------------------	---------------------------------	---------	-------------------------------	---

MANUSCRIPTS PUBLISHED/PRESENTED

?	Renal abnormalities induced by hydroxyurea (NSC-32065). ML Samuels, CD Howe. <u>Cancer Chemotherapy Reports</u> 40:9-13, 1964.	GI		
---	--	----	--	--